Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Free Subscription

Articles published in Br J Haematol

Retrieve available abstracts of 513 articles:
HTML format

Single Articles

    May 2024
    The CAR T-cell race: The rules of the game.
    Br J Haematol. 2024;204:1579-1581.
    PubMed     Abstract available

  2. ZHANG X, Tao C, Long F
    Haematoidin in chronic myelomonocytic leukaemia during irregular treatment with hydroxycarbamide.
    Br J Haematol. 2024;204:1569-1570.

  3. MISHRA AK, Burridge S, Espuelas MO, O'Reilly M, et al
    Practice guideline: Preparation for CAR T-cell therapy in children and young adults with B-acute lymphoblastic leukaemia.
    Br J Haematol. 2024;204:1687-1696.
    PubMed     Abstract available

  4. KRIEGER E, Qayyum R, Toor A
    Increased donor inhibitory KIR are associated with reduced GVHD and improved survival following HLA-matched unrelated donor HCT in paediatric acute leukaemia.
    Br J Haematol. 2024;204:1935-1943.
    PubMed     Abstract available

  5. LEBECQUE B, Besombes J, Dannus LT, De Antonio M, et al
    Faster clinical decisions in B-cell acute lymphoblastic leukaemia: A single flow cytometric 12-colour tube improves diagnosis and minimal residual disease follow-up.
    Br J Haematol. 2024;204:1872-1881.
    PubMed     Abstract available

  6. JO T, Ueda T, Akahoshi Y, Kondo T, et al
    First complete remission favours haploidentical haematopoietic stem cell transplantation with post-transplant cyclophosphamide over cord blood transplantation in acute lymphoblastic leukaemia.
    Br J Haematol. 2024;204:1913-1919.
    PubMed     Abstract available

  7. BOUKOUACI W, Rivera-Franco MM, Volt F, Lajnef M, et al
    HLA peptide-binding pocket diversity modulates immunological complications after cord blood transplant in acute leukaemia.
    Br J Haematol. 2024;204:1920-1934.
    PubMed     Abstract available

  8. BRILLEMBOURG H, Martinez-Cibrian N, Bachiller M, Alserawan L, et al
    The role of chimeric antigen receptor T cells targeting more than one antigen in the treatment of B-cell malignancies.
    Br J Haematol. 2024;204:1649-1659.
    PubMed     Abstract available

  9. LOH Z, Ashby M, Van Veldhuizen E, Li W, et al
    Arsenic-induced neurotoxicity in patients with acute promyelocytic leukaemia.
    Br J Haematol. 2024;204:1732-1739.
    PubMed     Abstract available

    April 2024
  10. LIU HC, Huang YJ, Jaing TH, Wu KH, et al
    Refining risk stratification in paediatric B-acute lymphoblastic leukaemia: Combining IKZF1(plus) and Day 15 MRD positivity.
    Br J Haematol. 2024;204:1344-1353.
    PubMed     Abstract available

  11. BOMMANNAN K, Arumugam JR, Radhakrishnan V, Sundersingh S, et al
    Relevance of CD20 antigen expression among paediatric patients with B-lineage acute lymphoblastic leukaemia.
    Br J Haematol. 2024;204:1367-1374.
    PubMed     Abstract available

  12. CHEN X, Li J, Yu L, Hu W, et al
    High-dose methotrexate pharmacokinetics and its impact on prognosis of paediatric acute lymphoblastic leukaemia patients: A population pharmacokinetic study.
    Br J Haematol. 2024;204:1354-1366.
    PubMed     Abstract available

  13. MOSQUERA ORGUEIRA A, Perez Encinas MM, Diaz Varela N, Wang YH, et al
    Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for improved risk stratification.
    Br J Haematol. 2024;204:1529-1535.
    PubMed     Abstract available

    The Mozart effect in chronic myeloid leukaemia.
    Br J Haematol. 2024;204:1139-1140.
    PubMed     Abstract available

  15. PATEL SA
    The heart of VIALE-A: Cardiac complications of hypomethylating agents and venetoclax in acute myeloid leukaemia.
    Br J Haematol. 2024;204:1137-1138.
    PubMed     Abstract available

  16. ZHANG T, Zhang Y, Zhou M, Zhang Z, et al
    Risk factors and survival analysis of human leukocyte antigen loss in relapsed acute myeloid leukaemia/myelodysplastic syndrome patients after allogeneic haematopoietic stem cell transplantation.
    Br J Haematol. 2024;204:1402-1413.
    PubMed     Abstract available

  17. ALCAZER V, Morisset S, Rea D, Legros L, et al
    Kinetics of molecular recurrence after tyrosine kinase inhibitor cessation in chronic phase chronic myelogenous leukaemia patients.
    Br J Haematol. 2024;204:1536-1539.

  18. JOHNSON IM, Karrar O, Rana M, Iftikhar M, et al
    Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents.
    Br J Haematol. 2024;204:1232-1237.
    PubMed     Abstract available

  19. NACHMIAS B, Aumann S, Haran A, Schimmer AD, et al
    Venetoclax resistance in acute myeloid leukaemia-Clinical and biological insights.
    Br J Haematol. 2024;204:1146-1158.
    PubMed     Abstract available

  20. ZUCENKA A, Griskevicius L
    Gilteritinib in combination with venetoclax, low-dose cytarabine and actinomycin D for relapsed or refractory FLT3-mutated acute myeloid leukaemia.
    Br J Haematol. 2024;204:1227-1231.
    PubMed     Abstract available

  21. SUWANNAYING K, Ong AA, Dhaduk R, Pei D, et al
    Quantitative computed tomography analysis of body composition changes in paediatric patients with acute lymphoblastic leukaemia.
    Br J Haematol. 2024;204:1335-1343.
    PubMed     Abstract available

    Therapy with hypomethlyating agents/venetoclax in patients with newly diagnosed acute myeloid leukaemia requiring admission to the intensive care unit: Possible reduction in side effects with preserved efficacy.
    Br J Haematol. 2024;204:1135-1136.
    PubMed     Abstract available

  23. LIANG P, Xie Y, Liu Z, Wang D, et al
    Venetoclax and hypomethylating agents in critically ill patients with newly diagnosed acute myeloid leukaemia.
    Br J Haematol. 2024;204:1219-1226.
    PubMed     Abstract available

  24. ROY MOULIK N, Keerthivasagam S, Pandey A, Agiwale J, et al
    Treatment and follow-up of children with chronic myeloid leukaemia in chronic phase (CML-CP) in the tyrosine kinase inhibitor (TKI) era-Two decades of experience from the Tata Memorial Hospital paediatric CML (pCML) cohort.
    Br J Haematol. 2024;204:1249-1261.
    PubMed     Abstract available

  25. MADERO-MARROQUIN R, DuVall AS, Saygin C, Wang P, et al
    Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors.
    Br J Haematol. 2024;204:1238-1242.
    PubMed     Abstract available

  26. LIGIA S, Passucci M, Assanto GM, D'Elia GM, et al
    Early clearance of hairy cell leukaemia in the bone marrow after first-line treatment with cladribine predicts a favourable outcome.
    Br J Haematol. 2024;204:1288-1292.
    PubMed     Abstract available

    March 2024
  27. LARIBI K, Poulain S, Willems L, Merabet F, et al
    Long-term results of Waldenstrom macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO).
    Br J Haematol. 2024 Mar 19. doi: 10.1111/bjh.19409.
    PubMed     Abstract available

  28. NG HL, Robinson ME, May PC, Innes AJ, et al
    Promoter-centred chromatin interactions associated with EVI1 expression in EVI1+3q- myeloid leukaemia cells.
    Br J Haematol. 2024;204:945-958.
    PubMed     Abstract available

  29. SUN H, Zhu Y, Li J, Zhao L, et al
    CSF3R P733T is a deleterious germline variant in acute leukaemia showing gain-of-function-like T618I mutation.
    Br J Haematol. 2024;204:e31-e33.

  30. SHIMONY S, Chen EC
    Tri-ing to decipher trisomy AML.
    Br J Haematol. 2024;204:751-752.
    PubMed     Abstract available

  31. TAN JY, Yeo YH, Tan MC, Chavez JC, et al
    Mortality trends of chronic lymphocytic leukaemia in the United States with the emergence of targeted therapy.
    Br J Haematol. 2024;204:1114-1117.

  32. ZHAO HG
    Should oligomonocytic CMML be classified as an independent disease entity?
    Br J Haematol. 2024;204:749-750.
    PubMed     Abstract available

  33. LAM SSY, Tsui SP, Fung CY, Saw NY, et al
    Distinct karyotypic and mutational landscape in trisomy AML.
    Br J Haematol. 2024;204:939-944.
    PubMed     Abstract available

  34. COPLAND M, Ariti C, Thomas IF, Upton L, et al
    A randomised evaluation of low-dose cytosine arabinoside plus lenalidomide versus single-agent low-dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI-1 trial.
    Br J Haematol. 2024;204:871-876.
    PubMed     Abstract available

  35. CASTANO-DIEZ S, Pomares H, Esteban D, Guijarro F, et al
    Characteristics and long-term outcome in a large series of chronic myelomonocytic leukaemia patients including 104 formerly referred to as oligomonocytic.
    Br J Haematol. 2024;204:892-897.
    PubMed     Abstract available

  36. LU Q, Qu W, Wen Y, Ke P, et al
    Single-cell RNA-seq reveals the links between the metabolic heterogeneity and cell identity in NBM and AML.
    Br J Haematol. 2024;204:1100-1104.

  37. RAVANDI F, Dohner H, Wei AH, Montesinos P, et al
    Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML-001.
    Br J Haematol. 2024;204:877-886.
    PubMed     Abstract available

  38. MONTALBAN-BRAVO G, Jabbour E, Borthakur G, Kadia T, et al
    Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents.
    Br J Haematol. 2024;204:898-909.
    PubMed     Abstract available

  39. CHEN N, Pan J, Zhou Y, Mao L, et al
    Gilteritinib-based combination therapy in adult relapsed/refractory FLT3-mutated acute myeloid leukaemia.
    Br J Haematol. 2024;204:861-870.
    PubMed     Abstract available

    February 2024
  40. COSTA A, Breccia M
    How to improve treatment-free remission eligibility in chronic myeloid leukaemia?
    Br J Haematol. 2024;204:434-448.
    PubMed     Abstract available

  41. PARDANANI A, Reichard K, Tefferi A
    Advanced systemic mastocytosis-Revised classification, new drugs and how we treat.
    Br J Haematol. 2024;204:402-414.
    PubMed     Abstract available

  42. FUJI S, Yuda S, Tada Y, Kano M, et al
    A treatment strategy to mitigate the adverse effect of pretransplant mogamulizumab on post-transplant clinical outcome in patients with aggressive ATL.
    Br J Haematol. 2024;204:e25-e27.

  43. WANG Z, Fan Z, Wu Z, Xuan L, et al
    PASS-ALL study of paediatric-inspired versus adult chemotherapy regimens on survival of high-risk Philadelphia-negative B-cell acute lymphoblastic leukaemia with allogeneic haematopoietic stem cell transplantation.
    Br J Haematol. 2024;204:628-637.
    PubMed     Abstract available

  44. KUMAR J, Ewalt MD, Zhang Y, Yao J, et al
    Novel identification of t(14;18)(q32;q21)/IGH::MALT1 in chronic lymphocytic leukaemia.
    Br J Haematol. 2024;204:561-565.
    PubMed     Abstract available

  45. NYQUIST OE, Dalgaard J, Spetalen S, Torkildsen S, et al
    Pathogenic DDX41 variants, possible response predictors to low-dose melphalan in hypo- and normocellular MDS and AML.
    Br J Haematol. 2024;204:724-729.

  46. NARDOZZA AM, Guarnera L, Travaglini S, Ottone T, et al
    Characterization of a novel IDH2-R159H mutation in acute myeloid leukaemia: Effects on cell metabolism and differentiation.
    Br J Haematol. 2024;204:719-723.

  47. RAMAMOORTHY S, Lebrecht D, Schanze D, Schanze I, et al
    Biallelic inactivation of the NF1 tumour suppressor gene in juvenile myelomonocytic leukaemia: Genetic evidence of driver function and implications for diagnostic workup.
    Br J Haematol. 2024;204:595-605.
    PubMed     Abstract available

  48. MARK C, Meshinchi S, Joyce B, Gibson B, et al
    Treatment outcomes of childhood PICALM::MLLT10 acute leukaemias.
    Br J Haematol. 2024;204:576-584.
    PubMed     Abstract available

  49. SHEN Y, Freeman JA, Kerridge I, Downe P, et al
    Repeated COVID-19 vaccination to maximum antibody response yields very low mortality and hospitalisation rates in patients with CLL and MBL.
    Br J Haematol. 2024;204:487-491.
    PubMed     Abstract available

  50. BAI L, Zhang ZX, Hu GH, Cheng YF, et al
    Long-term follow-up of haploidentical haematopoietic stem cell transplantation in paediatric patients with high-risk acute myeloid leukaemia: Report from a single centre.
    Br J Haematol. 2024;204:585-594.
    PubMed     Abstract available

    January 2024
  51. MIYASHITA N, Onozawa M, Matsukawa T, Mori A, et al
    Novel stratification for newly diagnosed acute myeloid leukaemia treated with venetoclax-based therapy in the real world: Hokkaido Leukemia Net Study.
    Br J Haematol. 2024 Jan 18. doi: 10.1111/bjh.19292.

  52. NAVRKALOVA V, Plevova K, Radova L, Porc J, et al
    Integrative NGS testing reveals clonal dynamics of adverse genomic defects contributing to a natural progression in treatment-naive CLL patients.
    Br J Haematol. 2024;204:240-249.
    PubMed     Abstract available

  53. HASSELBALCH HC, Skov V, Kjaer L, Larsen MK, et al
    Proof of concept of triple COMBI therapy to prohibit MPN progression to AML.
    Br J Haematol. 2024;204:16-18.
    PubMed     Abstract available

    How to discover the exceptional venetoclax responders in AML/MDS?
    Br J Haematol. 2024;204:14-15.

  55. GESTRICH CK, De Lancy SJ, Kresak A, Meyerson H, et al
    IGJ and SPATS2L immunohistochemistry sensitively and specifically identify BCR::ABL1+ and BCR::ABL1-like B-acute lymphoblastic leukaemia.
    Br J Haematol. 2024;204:229-239.
    PubMed     Abstract available

  56. BARON F, Nagler A, Galimard JE, Sanz J, et al
    Cord blood transplantation for AML: Comparable LFS in patients with de novo versus secondary AML in CR1, an ALWP/EBMT study.
    Br J Haematol. 2024;204:250-259.
    PubMed     Abstract available

  57. DE CASTRO FA, Mehdipour P, Chakravarthy A, Ettayebi I, et al
    Ratio of stemness to interferon signalling as a biomarker and therapeutic target of myeloproliferative neoplasm progression to acute myeloid leukaemia.
    Br J Haematol. 2024;204:206-220.
    PubMed     Abstract available

  58. NANAA A, He R, Foran JM, Badar T, et al
    Venetoclax plus hypomethylating agents in DDX41-mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patients.
    Br J Haematol. 2024;204:171-176.
    PubMed     Abstract available

    HTLV-1 and blood donation.
    Br J Haematol. 2024;204:29-30.
    PubMed     Abstract available

    December 2023
  60. HOKLAND P, Fernandez II, Freeman SD, Gjertsen BT, et al
    AML in the elderly-A global view.
    Br J Haematol. 2023;203:760-773.

  61. WU JF, Abid H, Szabo A, Abid MB, et al
    Impact of age on efficacy and safety of chimeric antigen receptor-T in B-cell acute lymphoblastic leukaemia-A systematic review and meta-analysis.
    Br J Haematol. 2023;203:e117-e120.

  62. HERRITY E, Pereira MP, Kim DDH
    Acute myeloid leukaemia relapse after allogeneic haematopoietic stem cell transplantation: Mechanistic diversity and therapeutic directions.
    Br J Haematol. 2023;203:722-735.
    PubMed     Abstract available

  63. MAHDI D, O'Nions J, Raj K, Baker R, et al
    Managing molecular relapse of acute myeloid leukaemia in early pregnancy: Is a watch and wait approach reasonable?
    Br J Haematol. 2023;203:e114-e116.

  64. QI P, Wang L, Li H, Wu Y, et al
    Venetoclax as a cytoreduction therapy for acute promyelocytic leukaemia: A single-centre experience.
    Br J Haematol. 2023;203:892-895.

  65. PERUSINI MA, Novitzky-Basso I, Atenafu EG, Forrest D, et al
    Final report of TKI discontinuation trial with dasatinib for the second attempt of treatment-free remission after failing the first attempt with imatinib: Treatment-free Remission Accomplished by Dasatinib (TRAD) study.
    Br J Haematol. 2023;203:781-791.
    PubMed     Abstract available

  66. CHIRIAC R, Humbert C, Mejri A, Debliquis A, et al
    Charcot-Leyden crystals in acute myeloid leukaemia associated with basophilia.
    Br J Haematol. 2023;203:699-700.

    November 2023
  67. NG JY, Joshi M, Choi P
    Frequency and outcomes of obinutuzumab-induced thrombocytopenia.
    Br J Haematol. 2023;203:668-672.
    PubMed     Abstract available

  68. BORLENGHI E, Roccaro AM, Cattaneo C
    Rethinking the definition of 'less intensive' for venetoclax-combining regimens in acute myeloid leukaemia patients.
    Br J Haematol. 2023;203:504-506.
    PubMed     Abstract available

  69. REYNOLDS G, Urbancic KF, Fong CY, Trubiano JA, et al
    Invasive fungal infection following venetoclax and posaconazole co-administration.
    Br J Haematol. 2023;203:593-598.
    PubMed     Abstract available

  70. OCADLIKOVA D, Lussana F, Fracchiolla N, Bonifacio M, et al
    Blinatumomab differentially modulates peripheral blood and bone marrow immune cell repertoire: A Campus ALL study.
    Br J Haematol. 2023;203:637-650.
    PubMed     Abstract available

  71. BOOTH E, Backx M, Joshi A, Nizami H, et al
    Disseminated invasive aspergillosis in a patient treated with ibrutinib for chronic lymphocytic leukaemia.
    Br J Haematol. 2023;203:499-500.

  72. DONNETTE M, Hamimed M, Ciccolini J, Sicard G, et al
    Cytidine deaminase status as a marker of response to azacytidine treatment in MDS and AML patients.
    Br J Haematol. 2023;203:625-636.
    PubMed     Abstract available

  73. MONTALBAN-BRAVO G, Kanagal-Shamanna R, Li Z, Hammond D, et al
    Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia.
    Br J Haematol. 2023;203:581-592.
    PubMed     Abstract available

  74. APOLITO V, Arrigo G, Vasseur L, Olivi M, et al
    Validation of SIE/SIES/GITMO consensus criteria for unfitness to predict early mortality and survival in acute myeloid leukaemia patients treated with hypomethylating agents and venetoclax.
    Br J Haematol. 2023;203:e98-e101.

    October 2023
  75. MARTINEZ-CIBRIAN N, Ortiz-Maldonado V, Espanol-Rego M, Blazquez A, et al
    The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma.
    Br J Haematol. 2023 Oct 31. doi: 10.1111/bjh.19170.
    PubMed     Abstract available

  76. PAN X, Chang Y, Ruan G, Wei F, et al
    Prognostic impact of FLT3-ITD mutation on NPM1(+) acute myeloid leukaemia patients and related molecular mechanisms.
    Br J Haematol. 2023;203:212-223.
    PubMed     Abstract available

  77. MAHDI D, Spiers J, Rampotas A, Polverelli N, et al
    Updates on accelerated and blast phase myeloproliferative neoplasms: Are we making progress?
    Br J Haematol. 2023;203:169-181.
    PubMed     Abstract available

  78. SEVERIN F, Mouawad N, Ruggeri E, Visentin A, et al
    Focal adhesion kinase activation by calcium-dependent calpain is involved in chronic lymphocytic leukaemia cell aggressiveness.
    Br J Haematol. 2023;203:224-236.
    PubMed     Abstract available

  79. TRAVAGLINI S, Gurnari C, Antonelli S, Marchesi F, et al
    Functional characterization and response to FLT3 inhibitors in acute myeloid leukaemia with a non-canonical FLT3 mutation: A proof of concept.
    Br J Haematol. 2023;203:327-330.

  80. EADIE LN, Rehn JA, Schutz CE, Heatley SL, et al
    Case report: Rare case of donor cell-derived T-cell acute lymphoblastic leukaemia in a female patient after receiving an allo-transplant from her male sibling.
    Br J Haematol. 2023;203:282-287.
    PubMed     Abstract available

    September 2023
  81. RHODES J
    FISH-ing for answers: Can genomic arrays add to our understanding of disease biology in low-risk chronic lymphocytic leukaemia?
    Br J Haematol. 2023;202:922-924.
    PubMed     Abstract available

    The (near) miracle of therapy in chronic myeloid leukaemia.
    Br J Haematol. 2023;202:919-921.

  83. PATNANA PK, Liu L, Frank D, Nimmagadda SC, et al
    Dose-dependent expression of GFI1 alters metabolism in the haematopoietic progenitors and MLL::AF9-induced leukaemic cells.
    Br J Haematol. 2023;202:1033-1048.
    PubMed     Abstract available

  84. HUA L, Yang N, Li Y, Huang K, et al
    Metformin sensitizes AML cells to venetoclax through endoplasmic reticulum stress-CHOP pathway.
    Br J Haematol. 2023;202:971-984.
    PubMed     Abstract available

  85. LI H, Yuan L, Wang P, Sheng Y, et al
    Clonal architecture and single-cell transcriptome landscape in Richter's syndrome.
    Br J Haematol. 2023;202:1055-1060.

  86. RIGOLIN GM, Traversa A, Caputo V, Del Giudice I, et al
    Additional lesions identified by genomic microarrays are associated with an inferior outcome in low-risk chronic lymphocytic leukaemia patients.
    Br J Haematol. 2023;202:953-959.
    PubMed     Abstract available

  87. DE JOHN KO, De Quintal H, Mathibe MD, Albertus N, et al
    A rare case of acute megakaryoblastic leukaemia with constitutional ring chromosome 21.
    Br J Haematol. 2023;202:912.

  88. SHAH NP, Garcia-Gutierrez V, Jimenez-Velasco A, Larson SM, et al
    Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREE.
    Br J Haematol. 2023;202:942-952.
    PubMed     Abstract available

  89. BRECCIA M, Saglio G
    Interferon in chronic myeloid leukaemia: Is it useful for treatment-free remission?
    Br J Haematol. 2023;202:1087-1088.
    PubMed     Abstract available

  90. HADDAD FG, Kourie HR, Saleh K
    Moving away from chemotherapy in newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2023;202:1084-1086.
    PubMed     Abstract available

  91. IRANI YD, Hughes A, Kok CH, Clarson J, et al
    Immune modulation in chronic myeloid leukaemia patients treated with nilotinib and interferon-alpha.
    Br J Haematol. 2023;202:1127-1136.
    PubMed     Abstract available

  92. FENG H, Fu Y, Cui Z, Zhou M, et al
    Histone demethylase PHF8 facilitates the development of chronic myeloid leukaemia by directly targeting BCR::ABL1.
    Br J Haematol. 2023;202:1178-1191.
    PubMed     Abstract available

  93. PESCHKE JC, Bergmann R, Mehnert M, Gonzalez Soto KE, et al
    FLT3-directed UniCAR T-cell therapy of acute myeloid leukaemia.
    Br J Haematol. 2023;202:1137-1150.
    PubMed     Abstract available

  94. PASTORE F, Gittinger H, Raab S, Tschuri S, et al
    Acute megakaryoblastic leukaemia shows high frequency of chromosome 1q aberrations and dismal outcome.
    Br J Haematol. 2023;202:1165-1177.
    PubMed     Abstract available

  95. XIE M, Lu Y, Ouyang G, Li X, et al
    Dasatinib plus prednisone as induction and consolidation for adults with Ph-positive acute lymphoblastic leukaemia: A single-arm, multicentre, phase 2 trial.
    Br J Haematol. 2023;202:1119-1126.
    PubMed     Abstract available

  96. MATSUMOTO K, Kakazu N, Imataki O, Kondo A, et al
    Hairy cell leukaemia with an IGH-BRAF fusion gene.
    Br J Haematol. 2023;202:e67-e70.

  97. BELHADJ M, Burroni B, Kosmider O, Willems L, et al
    Clinico-biological features, treatment and prognosis of primary myeloid sarcoma: A French retrospective multi-centric observational study.
    Br J Haematol. 2023;202:e50-e53.

    August 2023
  98. LAHERA A, Vela-Martin L, Lopez-Nieva P, Salgado RN, et al
    Comprehensive characterization of a novel, oncogenic and targetable SEPTIN6::ABL2 fusion in T-ALL.
    Br J Haematol. 2023;202:693-698.

  99. GE SS, Qiu QC, Dai HP, Shen XD, et al
    Mutation spectrum of FLT3 and significance of non-canonical FLT3 mutations in haematological malignancy.
    Br J Haematol. 2023;202:539-549.
    PubMed     Abstract available

  100. MA Z, Ye W, Wang J, Huang X, et al
    Glutamate dehydrogenase 1: A novel metabolic target in inhibiting acute myeloid leukaemia progression.
    Br J Haematol. 2023;202:566-577.
    PubMed     Abstract available

  101. ZHOU L, Fu W, Wu S, Xu K, et al
    Derivation and validation of a novel score for early prediction of severe CRS after CAR-T therapy in haematological malignancy patients: A multi-centre study.
    Br J Haematol. 2023;202:517-524.
    PubMed     Abstract available

  102. NI SC, Lin CC
    Pseudothrombocytosis in Acute Myeloid Leukaemia.
    Br J Haematol. 2023;202:456.

  103. MILADINOVIC M, Klusmann JH
    Influenza A (H1N1) virus induced long-term remission in a refractory acute myeloid leukaemia.
    Br J Haematol. 2023;202:713-714.
    PubMed     Abstract available

  104. HUO WX, Wen Q, Zhang XH, Xu LP, et al
    Outcomes of haploidentical haematopoietic stem cell transplantation for adolescent and young adults with acute myeloid leukaemia.
    Br J Haematol. 2023;202:856-865.
    PubMed     Abstract available

  105. NG LIET HING M, Ryland GL, Nguyen T, Tiong IS, et al
    Variant acute promyelocytic leukaemia with novel NAB2::RARA fusion shows clinical all-trans retinoic acid and arsenic trioxide sensitivity.
    Br J Haematol. 2023;202:893-896.

  106. YOU L, Liu Y, Chen N, Zhu L, et al
    Influenza A (H1N1) virus induced long-term remission in a refractory acute myeloid leukaemia.
    Br J Haematol. 2023;202:745-748.
    PubMed     Abstract available

  107. RIVA G, Luppi M, Tagliafico E
    From gating to computational flow cytometry: Exploiting artificial intelligence for MRD diagnostics.
    Br J Haematol. 2023;202:715-717.
    PubMed     Abstract available

  108. NGUYEN PC, Nguyen V, Baldwin K, Kankanige Y, et al
    Computational flow cytometry provides accurate assessment of measurable residual disease in chronic lymphocytic leukaemia.
    Br J Haematol. 2023;202:760-770.
    PubMed     Abstract available

  109. KUSUDA M, Nakasone H, Yoshimura K, Okada Y, et al
    Gene expression and TCR amino acid sequences selected by HLA-A02:01-restricted CTLs specific to HTLV-1 in ATL patients.
    Br J Haematol. 2023;202:578-588.
    PubMed     Abstract available

  110. LOKE J, Upasani V, Gaskell C, Fox S, et al
    Defective T-cell response to COVID-19 vaccination in acute myeloid leukaemia and myelodysplastic syndromes.
    Br J Haematol. 2023;202:498-503.
    PubMed     Abstract available

  111. SARTOR C, Brunetti L, Audisio E, Cignetti A, et al
    A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure.
    Br J Haematol. 2023;202:599-607.
    PubMed     Abstract available

  112. BORRILL R, Poulton K, Kusyk L, Routledge A, et al
    Granulocyte transfusion during cord blood transplant for relapsed, refractory AML is associated with massive CD8(+) T-cell expansion, significant cytokine release syndrome and induction of disease remission.
    Br J Haematol. 2023;202:589-598.
    PubMed     Abstract available

    July 2023
  113. KASSEM AM, Keinath MC, Adler JA, Gadde R, et al
    ZBTB16::RARA variant acute promyelocytic leukemia (vAPL) treated with gemtuzumab ozogamicin (GO) with unique pathology and genetic findings.
    Br J Haematol. 2023 Jul 26. doi: 10.1111/bjh.18950.

  114. FALINI B, Cardinali V, Brunetti L, Martelli MP, et al
    NPM1-mutated AML with starry sky pattern.
    Br J Haematol. 2023;202:8.

  115. HUO L, Zhang Z, Zhou H, Xie J, et al
    Causative germline variant p.Y259C of DDX41 recurrently identified in acute lymphoblastic leukaemia.
    Br J Haematol. 2023;202:199-203.

  116. DOAN A, Huang HKT, Hadar AJ, Malvar J, et al
    Efficacy and safety of FLAG-IDA as front-line therapy in de novo paediatric acute myeloid leukaemia population.
    Br J Haematol. 2023;202:e3-e6.

  117. ZHU X, Jiang Q, Lu J, Sun Y, et al
    COVID-19 infection in patients with haematological malignancies: A single-centre survey in the latest Omicron wave in China.
    Br J Haematol. 2023;202:31-39.
    PubMed     Abstract available

  118. ZHANG X, Wang Z, Sun J, Liu L, et al
    New insights into the clinical characteristics of SETD2-mutated acute myeloid leukaemia.
    Br J Haematol. 2023;202:111-115.
    PubMed     Abstract available

    Computational analysis of a microRNA signature for poor prognosis suggests a microRNA-controlled stemness pathway in paediatric acute leukaemia.
    Br J Haematol. 2023;202:11-12.
    PubMed     Abstract available

  120. FIGUEROA-MORA R, Rampotas A, Halperin D, Worth T, et al
    Venetoclax ramp-up strategies for chronic lymphocytic leukaemia in the United Kingdom: a real world multicentre retrospective study.
    Br J Haematol. 2023;202:48-53.
    PubMed     Abstract available

  121. ESPERANZA-CEBOLLADA E, Gomez-Gonzalez S, Perez-Jaume S, Vega-Garcia N, et al
    A miRNA signature related to stemness identifies high-risk patients in paediatric acute myeloid leukaemia.
    Br J Haematol. 2023;202:96-110.
    PubMed     Abstract available

  122. JO T, Arai Y, Oshima S, Kondo T, et al
    Prognostic impact of complex and/or monosomal karyotypes in post-transplant poor cytogenetic acute myeloid leukaemia: A quantitative approach.
    Br J Haematol. 2023;202:356-368.
    PubMed     Abstract available

  123. SYSTCHENKO T, Chomel JC, Gallego-Hernanz P, Moya N, et al
    Combination of azacitidine, venetoclax and ruxolitinib in blast phase myeloproliferative neoplasms.
    Br J Haematol. 2023;202:284-288.
    PubMed     Abstract available

  124. STRULLU M, Fenneteau O, Lainey E
    Cannibalism in an ETV6::RUNX1 paediatric B acute lymphoblastic leukaemia.
    Br J Haematol. 2023;202:211.

  125. LI T, Zhang Y, Wang K, Zhou H, et al
    Leukaemic blasts in a urine specimen in acute myeloid leukaemia with CEBPA mutation.
    Br J Haematol. 2023;202:212.

  126. LV M, Liu L, He Y, Yang D, et al
    Outcomes of allogeneic or autologous stem cell transplantation followed by maintenance chemotherapy in adult patient with B-ALL in CR1 with no detectable minimal residual disease.
    Br J Haematol. 2023;202:369-378.
    PubMed     Abstract available

  127. OFVERHOLM I, Rezayee F, Heyman M, Harila A, et al
    The prognostic impact of IKZF1 deletions and UKALL genetic classifiers in paediatric B-cell precursor acute lymphoblastic leukaemia treated according to NOPHO 2008 protocols.
    Br J Haematol. 2023;202:384-392.
    PubMed     Abstract available

  128. WANG W, Li X, Qin X, Miao Y, et al
    Germline Neurofibromin 1 mutation enhances the anti-tumour immune response and decreases juvenile myelomonocytic leukaemia tumourigenicity.
    Br J Haematol. 2023;202:328-343.
    PubMed     Abstract available

  129. GURNEY M, Chekkaf I, Baranwal A, Basmaci R, et al
    The clinical and molecular spectrum of ETV6 mutated myeloid neoplasms.
    Br J Haematol. 2023;202:279-283.
    PubMed     Abstract available

    June 2023
  130. MUNTANOLA A, Villalobos MT, Gonzalez-Villambrosia S, Rodriguez-Salazar MJ, et al
    Low-risk HPLLs/ABC score patients with splenic marginal zone lymphoma can be safely managed without treatment: Results from a prospective Spanish study.
    Br J Haematol. 2023 Jun 30. doi: 10.1111/bjh.18912.
    PubMed     Abstract available

  131. TURNER R, Quach H, Horvath N, Kerridge I, et al
    Response adaptive salvage with KTd and ASCT for functional high-risk multiple myeloma-The Australasian Leukemia and Lymphoma Group (ALLG) MM17 Trial.
    Br J Haematol. 2023 Jun 18. doi: 10.1111/bjh.18914.
    PubMed     Abstract available

  132. LIU Y, Zhu L, Lv Z, Mao L, et al
    Venetoclax plus azacitidine and LDAC induced high response rates in acute myeloid leukaemia in routine clinical practice.
    Br J Haematol. 2023;201:995-999.

  133. XIE X, Zhang W, Zhou X, Ye Z, et al
    Abemaciclib drives the therapeutic differentiation of acute myeloid leukaemia stem cells.
    Br J Haematol. 2023;201:940-953.
    PubMed     Abstract available

  134. VAINER N, Aarup K, Andersen MA, Wind-Hansen L, et al
    Real-world outcomes upon second-line treatment in patients with chronic lymphocytic leukaemia.
    Br J Haematol. 2023;201:874-886.
    PubMed     Abstract available

  135. RIEU JB, Canali A, Thene E, Tavitian S, et al
    Acute promyelocytic leukaemia associated with atypical basophilia.
    Br J Haematol. 2023;201:1017.

  136. YOKOYAMA S, Onozawa M, Yoshida S, Miyashita N, et al
    Subclinical minute FLT3-ITD clone can be detected in clinically FLT3-ITD-negative acute myeloid leukaemia at diagnosis.
    Br J Haematol. 2023;201:1144-1152.
    PubMed     Abstract available

  137. SIMOES C, Villar S, Ariceta B, Garces JJ, et al
    Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia.
    Br J Haematol. 2023;201:1239-1244.

  138. BRONSTEIN Y, Levi S, Herishanu Y
    Improved outcomes in patients with chronic lymphocytic leukaemia infected during the omicron BA.5 subvariant surge.
    Br J Haematol. 2023;201:1125-1128.
    PubMed     Abstract available

  139. DULUCQ S, Rigal-Huguet F, Nicolini FE, Cony-Makhoul P, et al
    Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment-free remission period after imatinib discontinuation: Results of the French Nilo post-STIM study.
    Br J Haematol. 2023;201:1116-1124.
    PubMed     Abstract available

  140. MENEZES DL, See WL, Risueno A, Tsai KT, et al
    Oral azacitidine modulates the bone marrow microenvironment in patients with acute myeloid leukaemia in remission: A subanalysis from the QUAZAR AML-001 trial.
    Br J Haematol. 2023;201:1129-1143.
    PubMed     Abstract available

  141. NAGLER A, Labopin M, Dholaria B, Blaise D, et al
    Impact of measurable residual disease on outcomes of unrelated donor haematopoietic cell transplantation with post-transplant cyclophosphamide in AML in first complete remission.
    Br J Haematol. 2023;201:1169-1178.
    PubMed     Abstract available

  142. ISHIDA H, Imamura T, Tatebe Y, Ishihara T, et al
    Impact of asparaginase discontinuation on outcomes of children with acute lymphoblastic leukaemia receiving the Japan Association of Childhood Leukaemia Study ALL-02 protocol.
    Br J Haematol. 2023;201:1200-1208.
    PubMed     Abstract available

    May 2023
  143. PUCKRIN R, Owen C, Stewart D, Peters A, et al
    Real-world management of small lymphocytic lymphoma as chronic lymphocytic leukaemia versus an indolent non-Hodgkin lymphoma.
    Br J Haematol. 2023 May 25. doi: 10.1111/bjh.18879.

  144. SAVOY L, Long N, Lee H, Chen R, et al
    CDK12/13 dual inhibitors are potential therapeutics for acute myeloid leukemia.
    Br J Haematol. 2023 May 14. doi: 10.1111/bjh.18843.

  145. JEDIDI I, Krichen I, Chaari M, Louati N, et al
    Auer-rod like inclusions in mature neutrophils of an early T cell precursor lymphoblastic leukaemia patient after SARS-CoV-2 infection.
    Br J Haematol. 2023;201:378.

  146. LUNDIN-STROM KB, Biloglav A, Castor A, Olsson-Arvidsson L, et al
    Acquired uniparental isodisomies involving chromosome 12 in paediatric B-cell precursor acute lymphoblastic leukaemia: Associations with chromosome 21 gains and SH2B3 mutations.
    Br J Haematol. 2023;201:585-588.

  147. WANG H, Yao Y, Mao L, Lou Y, et al
    Venetoclax plus '2 + 5' modified intensive chemotherapy with daunorubicin and cytarabine in fit elderly patients with untreated de novo acute myeloid leukaemia: a single-centre retrospective analysis.
    Br J Haematol. 2023;201:568-572.

  148. MAURO FR, Visentin A, Giannarelli D, Molinari MC, et al
    Pre-exposure prophylaxis with tixagevimab/cilgavimab in patients with chronic lymphocytic leukaemia treated with targeted agents.
    Br J Haematol. 2023;201:564-567.

  149. JING CB, Prutsch N, He S, Zimmerman MW, et al
    Synthetic lethal targeting of TET2-mutant haematopoietic stem and progenitor cells by XPO1 inhibitors.
    Br J Haematol. 2023;201:489-501.
    PubMed     Abstract available

  150. CARRILLO-TORNEL S, Chen-Liang TH, Zurdo M, Puiggros A, et al
    NOTCH1 mutation in chronic lymphocytic leukaemia is associated with an enhanced cell cycle G1/S transition and specific cyclin overexpression: Preclinical ground for targeted inhibition.
    Br J Haematol. 2023;201:470-479.
    PubMed     Abstract available

  151. TIACCI E, Mancini A, Marchetti M, D'Elia GM, et al
    SARS-CoV-2 infection and vaccination in patients with hairy-cell leukaemia.
    Br J Haematol. 2023;201:411-416.
    PubMed     Abstract available

  152. JONART LM, Ostergaard J, Brooks A, Fitzpatrick G, et al
    CXCR4 antagonists disrupt leukaemia-meningeal cell adhesion and attenuate chemoresistance.
    Br J Haematol. 2023;201:459-469.
    PubMed     Abstract available

  153. POPOV A, Tsaur G, Verzhbitskaya T, Riger T, et al
    Comparison of minimal residual disease measurement by multicolour flow cytometry and PCR for fusion gene transcripts in infants with acute lymphoblastic leukaemia with KMT2A gene rearrangements.
    Br J Haematol. 2023;201:510-519.
    PubMed     Abstract available

  154. COLLIGNON C, Domenech C, Ducassou S, Pluchart C, et al
    Temporary contraindication to chemotherapy due to toxicity: blinatumomab's effectiveness in paediatric patients with B-acute lymphoblastic leukaemia.
    Br J Haematol. 2023;201:e42-e45.

  155. CHEN R, Atenafu EG, Seki J, Liu X, et al
    Venous thromboembolism incidence associated with pegylated asparaginase (ASP) compared to the native L-ASP: A retrospective analysis with an ASP-based protocol in adult patients with acute lymphoblastic leukaemia.
    Br J Haematol. 2023;201:645-652.
    PubMed     Abstract available

  156. LAHERA A, Lopez-Nieva P, Alarcon H, Marin-Rubio JL, et al
    SOCS3 deregulation contributes to aberrant activation of the JAK/STAT pathway in precursor T-cell neoplasms.
    Br J Haematol. 2023;201:718-724.
    PubMed     Abstract available

  157. HAMA A, Taga T, Tomizawa D, Muramatsu H, et al
    Haematopoietic cell transplantation for children with acute megakaryoblastic leukaemia without Down syndrome.
    Br J Haematol. 2023;201:747-756.
    PubMed     Abstract available

  158. KARLSSON L, Cheuk D, De Moerloose B, Hasle H, et al
    Characteristics and outcome of primary resistant disease in paediatric acute myeloid leukaemia.
    Br J Haematol. 2023;201:757-765.
    PubMed     Abstract available

    April 2023
  159. CASTAGNA L, Patti K, Mule A
    Don't forget cord blood in non-remission acute myeloid leukaemia!
    Br J Haematol. 2023;201:11-12.
    PubMed     Abstract available

  160. ZHENG Y, Weng X, Hu D, He J, et al
    Identification of a signature based on non-apoptotic regulatory cell death to improve prognosis prediction in acute myeloid leukaemia.
    Br J Haematol. 2023;201:95-105.
    PubMed     Abstract available

  161. SORCINI D, De Falco F, Gargaro M, Bozza S, et al
    Immune correlates of protection by vaccine against SARS-CoV-2 in patients with chronic lymphocytic leukaemia.
    Br J Haematol. 2023;201:45-57.
    PubMed     Abstract available

  162. MATSUDA K, Konuma T, Fuse K, Masuko M, et al
    Comparison of transplant outcomes between haploidentical transplantation and single cord blood transplantation in non-remission acute myeloid leukaemia: A nationwide retrospective study.
    Br J Haematol. 2023;201:106-113.
    PubMed     Abstract available

  163. DEL GIUDICE I, Cappelli LV, Delgado J, Niemann CU, et al
    Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature.
    Br J Haematol. 2023;201:353-356.

  164. WANG YH, Yao CY, Lin CC, Gurashi K, et al
    A three-gene leukaemic stem cell signature score is robustly prognostic in chronic myelomonocytic leukaemia.
    Br J Haematol. 2023;201:302-307.
    PubMed     Abstract available

  165. MA H, Wang S, O'Brien S, Kern M, et al
    How we approach the perioperative management of patients with chronic lymphocytic leukaemia receiving continuous cancer-directed therapies.
    Br J Haematol. 2023;201:215-221.
    PubMed     Abstract available

  166. SALOMAO N, Maslah N, Giulianelli A, Drevon L, et al
    Reduced murine double minute 2 and 4 protein, but not messenger RNA, expression is associated with more severe disease in myelodysplastic syndromes and acute myeloblastic leukaemia.
    Br J Haematol. 2023;201:234-248.
    PubMed     Abstract available

  167. SINGH C, Yanamandra U, Karunakaran P, Jindal N, et al
    Long-term real-world outcomes of patients with acute promyelocytic leukaemia treated with arsenic trioxide and all-trans retinoic acid without chemotherapy-a retrospective, single-centre study.
    Br J Haematol. 2023;201:249-255.
    PubMed     Abstract available

    March 2023
  168. SPACEK M, Smolej L, Simkovic M, Nekvindova L, et al
    Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR).
    Br J Haematol. 2023 Mar 27. doi: 10.1111/bjh.18736.
    PubMed     Abstract available

  169. SHEN K, Yang C
    Occult optic nerve neurolymphomatosis of T-lymphoblastic lymphoma detected by PET/MRI.
    Br J Haematol. 2023 Mar 27. doi: 10.1111/bjh.18725.

  170. ROUZAUD C, Vercellino L, De Kerviler E, Raffoux E, et al
    Prognostic value of PET/CT and CT in T-cell lymphoblastic lymphoma/leukaemia patients: A retrospective cohort study of 145 patients.
    Br J Haematol. 2023 Mar 8. doi: 10.1111/bjh.18707.

  171. EL HUSSEIN S, Wang W
    Plasmacytoid dendritic cells in the setting of myeloid neoplasms: Diagnostic guide to challenging pathologic presentations.
    Br J Haematol. 2023;200:545-555.
    PubMed     Abstract available

  172. FRISCH A, Rowe JM, Ofran Y
    The increasingly blurred line between induction, consolidation and maintenance in acute myeloid leukaemia.
    Br J Haematol. 2023;200:556-562.
    PubMed     Abstract available

  173. MATSUDA K, Konuma T, Yanada M
    Cord blood versus haploidentical transplantations for non-remission acute myeloid leukaemia: Authors' reply.
    Br J Haematol. 2023;200:678-679.

  174. SCARADAVOU A, Boelens JJ
    Lower probability of relapse after myeloablative cord blood transplantation for patients with refractory AML.
    Br J Haematol. 2023;200:676-677.

  175. MUSSAI F, De Santo C, Cheng P, Thomas IF, et al
    A randomised evaluation of low-dose Ara-C plus pegylated recombinant arginase BCT-100 versus low dose Ara-C in older unfit patients with acute myeloid leukaemia: Results from the LI-1 trial.
    Br J Haematol. 2023;200:573-578.
    PubMed     Abstract available

  176. CHOI Y, Choi EJ, Park HS, Lee JH, et al
    A uniform conditioning regimen of busulfan, fludarabine, and antithymocyte globulin for allogeneic haematopoietic cell transplantation from haploidentical family, matched sibling, or unrelated donors-A single-centre, prospective, explorative study.
    Br J Haematol. 2023;200:608-621.
    PubMed     Abstract available

  177. AGUILAR NAVARRO AG, Tikhonova AN
    Treatment response in acute myeloid leukaemia-Clues in the biopsy core.
    Br J Haematol. 2023;200:691-693.
    PubMed     Abstract available

  178. TREABA DO, Bonal DM, Chorzalska A, Castillo-Martin M, et al
    Transcriptomics of acute myeloid leukaemia core bone marrow biopsies reveals distinct therapy response-specific osteo-mesenchymal profiles.
    Br J Haematol. 2023;200:740-754.
    PubMed     Abstract available

    February 2023
  179. MESZAROS N, Lind K, Sehlke R, Vilagos B, et al
    Influence of cryopreservation on drug responses and gene expression of AML cells: Implications for the use of biobanked tissues.
    Br J Haematol. 2023;200:e32-e36.

  180. MANGUM DS, Bishop JD, Zhou Y, Cheng C, et al
    Characterisation of children and adolescents with acute lymphoblastic leukaemia who presented without peripheral blood blasts at diagnosis.
    Br J Haematol. 2023;200:338-343.
    PubMed     Abstract available

  181. CHATTERJEE G, Patkar N
    United we stand, divided we fall. Multicentre standardization of measurable residual disease assessment in acute leukaemia is the way forward.
    Br J Haematol. 2023;200:277-279.
    PubMed     Abstract available

  182. BARNES EJ, Eide CA, Kaempf A, Bottomly D, et al
    Secondary fusion proteins as a mechanism of BCR::ABL1 kinase-independent resistance in chronic myeloid leukaemia.
    Br J Haematol. 2023;200:323-328.
    PubMed     Abstract available

  183. IKOMA-COLTURATO MRV, Bertolucci CM, Conti-Spilari JE, Oliveira E, et al
    Multicentric standardization of minimal/measurable residual disease in B-cell precursor acute lymphoblastic leukaemia using next-generation flow cytometry in a low/middle-level income country.
    Br J Haematol. 2023;200:381-384.

  184. KULIS M, Martin-Subero JI
    Integrative epigenomics in chronic lymphocytic leukaemia: Biological insights and clinical applications.
    Br J Haematol. 2023;200:280-290.
    PubMed     Abstract available

  185. GOURSAUD L, Berthon C, Quesnel B
    Successful bridging to cell therapy for relapsed/refractory acute lymphoblastic leukaemia with a combination of venetoclax and PEG-asparaginase.
    Br J Haematol. 2023;200:e37-e39.

  186. RAKOTOARIVELO ZH, Lefebvre T, Lamarque M, Harzallah I, et al
    Bundles of Auer rods in mature neutrophils in an acute myeloid leukaemia patient with inv(16)(p13.1q22) CBFB-MYH 11.
    Br J Haematol. 2023;200:398.

  187. TIAN C, Chen Z, Wang L, Si J, et al
    Over expression of ubiquitin-conjugating enzyme E2O in bone marrow mesenchymal stromal cells partially attenuates acute myeloid leukaemia progression.
    Br J Haematol. 2023;200:476-488.
    PubMed     Abstract available

  188. HUANG T, Xu L, Zhang X, Chang Y, et al
    Haploidentical haematopoietic stem cell transplantation for TP53-mutated acute myeloid leukaemia.
    Br J Haematol. 2023;200:494-505.
    PubMed     Abstract available

  189. MADRY K, Lis K, Fenaux P, Bowen D, et al
    Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registry.
    Br J Haematol. 2023;200:451-461.
    PubMed     Abstract available

  190. DARGENIO M, Bonifacio M, Chiaretti S, Vitale A, et al
    Incidence, treatment and outcome of central nervous system relapse in adult acute lymphoblastic leukaemia patients treated front-line with paediatric-inspired regimens: A retrospective multicentre Campus ALL study.
    Br J Haematol. 2023;200:440-450.
    PubMed     Abstract available

  191. GJAERDE LK, Jakobsen LH, Juhl-Christensen C, Olesen G, et al
    Trends in survival and cure after allogeneic haematopoietic cell transplantation for acute myeloid leukaemia from 2000 to 2020: A Danish population-based cohort study.
    Br J Haematol. 2023;200:e40-e43.

    January 2023
  192. WILSON J
    Pseudo-faggot cells in splenic marginal zone lymphoma.
    Br J Haematol. 2023 Jan 6. doi: 10.1111/bjh.18621.

  193. OLOFSEN PA, Bosch DA, de Looper HWJ, van Strien PMH, et al
    Truncated CSF3 receptors induce pro-inflammatory responses in severe congenital neutropenia.
    Br J Haematol. 2023;200:79-86.
    PubMed     Abstract available

  194. ZHANG T, Liu X, Fei H, Zhang L, et al
    Improved myeloablative conditioning regimen for allogeneic stem cell transplantation in adult patients with chronic myelomonocytic leukaemia.
    Br J Haematol. 2023;200:256-260.

  195. PAUL SR, Rosing DR, Haigney MC, Peer CJ, et al
    Cardiac toxicity in a pilot study of duvelisib and ibrutinib combination therapy for chronic lymphocytic leukaemia.
    Br J Haematol. 2023;200:261-263.

    Higher than normal mitochondrial DNA content associated with better outcome in acute promyelocytic leukaemia? Maybe.
    Br J Haematol. 2023;200:126-127.
    PubMed     Abstract available

  197. GURNARI C, Pagliuca S
    Digging into the HLA pockets: A new association with acute leukaemias.
    Br J Haematol. 2023;200:123-125.
    PubMed     Abstract available

  198. MEHTA P, Telford N, Wragg C, Dillon R, et al
    Recommendations for laboratory testing of UK patients with acute myeloid leukaemia.
    Br J Haematol. 2023;200:150-159.

  199. BOUKOUACI W, Rivera-Franco MM, Volt F, Wu CL, et al
    Comparative analysis of the variability of the human leukocyte antigen peptide-binding pockets in patients with acute leukaemia.
    Br J Haematol. 2023;200:197-209.
    PubMed     Abstract available

  200. PEREIRA-MARTINS DA, Coelho-Silva JL, Weinhauser I, Franca-Neto PL, et al
    Clinical significance of mitochondrial DNA content in acute promyelocytic leukaemia.
    Br J Haematol. 2023;200:170-174.
    PubMed     Abstract available

  201. ROY L, Chomel JC, Guilhot J, Guerci-Bresler A, et al
    Dasatinib plus Peg-Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA-PegIFN study).
    Br J Haematol. 2023;200:175-186.
    PubMed     Abstract available

    December 2022
  202. LI H, Xiang X, Ding H, Yu J, et al
    Differentiation therapy using low-dose venetoclax in a variant acute promyelocytic leukaemia carrying ZBTB16-RARA.
    Br J Haematol. 2022;199:768-771.

  203. CANALI A, Rieu JB
    Morphological characterization of acute myeloid leukaemia with t(11;17)(q23;q21)/ZBTB16::RARA fusion.
    Br J Haematol. 2022;199:638.

  204. WEI S, Gu R, Song Y, Yan Z, et al
    Early-salvage therapy with venetoclax-based regimens for induction failure and poor early response acute lymphoblastic leukaemia: A retrospective case series of 13 patients.
    Br J Haematol. 2022;199:772-776.

  205. ATKINS O, Mirvis E, Maynard S, Katsomitrou V, et al
    Acute myeloid leukaemia presenting with Sweet syndrome.
    Br J Haematol. 2022;199:637.

  206. MUNIR T, Emmerson J, Hockaday A, Oughton JB, et al
    Obinutuzumab as consolidation after chemo-immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial.
    Br J Haematol. 2022;199:707-719.
    PubMed     Abstract available

  207. COPLAND M
    Treatment of blast phase chronic myeloid leukaemia: A rare and challenging entity.
    Br J Haematol. 2022;199:665-678.
    PubMed     Abstract available

    November 2022
  208. DONG Q, Wang Y, Xiu Y, Sakr H, et al
    Clonally related composite chronic lymphocytic leukaemia and mantle cell lymphoma.
    Br J Haematol. 2022 Nov 14. doi: 10.1111/bjh.18565.

    ATM serine/threonine kinase germline mutations in chronic lymphocytic leukaemia come in different flavours.
    Br J Haematol. 2022;199:307-309.

  210. PETRACKOVA A, Savara J, Turcsanyi P, Gajdos P, et al
    Rare germline ATM variants of uncertain significance in chronic lymphocytic leukaemia and other cancers.
    Br J Haematol. 2022;199:371-381.
    PubMed     Abstract available

  211. LI T, Wu P, Wang A, Chen M, et al
    A rare case of transformation from relapsed acute monocytic leukaemia with KMT2A::MLLT10 to acute megakaryoblastic leukaemia.
    Br J Haematol. 2022;199:305.

  212. FORDHAM NJ, Bartram J, Ghorashian S, O'Connor D, et al
    What is the diagnostic yield of bone marrow aspiration to exclude leukaemia prior to systemic treatment in juvenile idiopathic arthritis?
    Br J Haematol. 2022;199:447-451.

    Asciminib for chronic myeloid leukaemia: Next questions.
    Br J Haematol. 2022;199:322-331.
    PubMed     Abstract available

  214. WAN Y, Zhang H, Zhang L, Cai J, et al
    Extended vincristine and dexamethasone pulse therapy may not be necessary for children with TCF3-PBX1 positive acute lymphoblastic leukaemia.
    Br J Haematol. 2022;199:587-596.
    PubMed     Abstract available

  215. WANG Y, Chen S, Chi P, Nie R, et al
    Survival prediction optimization of acute myeloid leukaemia based on T-cell function-related genes and plasma proteins.
    Br J Haematol. 2022;199:572-586.
    PubMed     Abstract available

  216. KRISTENSEN DT, Nielsen LB, Jakobsen LHK, Kristensen TC, et al
    Effects of chemotherapy dose reductions in overweight patients with acute myeloid leukaemia: A Danish nationwide cohort study.
    Br J Haematol. 2022;199:539-548.
    PubMed     Abstract available

  217. ZHAO C, Wang S, Wang K
    Mutual exclusivity between the fusion gene CBFB::MYH11 and somatic mitochondrial mutations in acute myeloid leukaemia.
    Br J Haematol. 2022;199:e25-e29.

  218. QIANG X, Chen S, Chen X
    Peritoneal infiltration by leukaemic promyelocytes in acute promyelocytic leukaemia at initial diagnosis.
    Br J Haematol. 2022;199:475.

  219. KOTMAYER L, Romero-Moya D, Marin-Bejar O, Kozyra E, et al
    GATA2 deficiency and MDS/AML: Experimental strategies for disease modelling and future therapeutic prospects.
    Br J Haematol. 2022;199:482-495.
    PubMed     Abstract available

    October 2022
  220. ANDERSSON NG, Rathe M, Molle I, Jarvis KB, et al
    A survey on thromboprophylaxis and coagulation assessment in children and young adults with acute lymphoblastic leukaemia (ALL) in the Nordic and Baltic countries: Different practices of assessment and management.
    Br J Haematol. 2022;199:117-121.
    PubMed     Abstract available

  221. BARRETT J
    Screening for mercaptopurine intolerance in ALL - target the genes or their product?
    Br J Haematol. 2022;199:173-174.
    PubMed     Abstract available

  222. DENNIS M, Copland M, Kaur H, Kell J, et al
    Management of older patients with frailty and acute myeloid leukaemia: A British Society for Haematology good practice paper.
    Br J Haematol. 2022;199:205-221.

  223. TANAKA Y, Urayama KY, Mori M, Arakawa Y, et al
    Prominence of NUDT15 genetic variation associated with 6-mercaptopurine tolerance in a genome-wide association study of Japanese children with acute lymphoblastic leukaemia.
    Br J Haematol. 2022;199:260-269.
    PubMed     Abstract available

  224. YOSHIDA M, Brown SA, Moriyama T, Nishii R, et al
    Low NUDT15 expression levels due to biallelic NUDT15 variants and 6-mercaptopurine intolerance.
    Br J Haematol. 2022;199:270-276.
    PubMed     Abstract available

  225. DILLON J, Mykytiv V, Keenan C, Mullaney B, et al
    Management of a patient with acute myeloid leukaemia with a diagnosis of type 2 von Willebrand disease and a novel variant within the von Willebrand factor (VWF) gene.
    Br J Haematol. 2022;199:e5-e7.

  226. ALSOUQI A, Rothenberger SD, Boyiadzis M, Lontos K, et al
    Time from diagnosis to treatment is associated with survival in patients with acute myeloid leukaemia: An analysis of 55 985 patients from the National Cancer Database.
    Br J Haematol. 2022;199:256-259.
    PubMed     Abstract available

  227. HAMPEL PJ, Rabe KG, Call TG, Ding W, et al
    Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia.
    Br J Haematol. 2022;199:239-244.
    PubMed     Abstract available

    September 2022
  228. GREINER J, Goetz M, Schuler PJ, Bulach C, et al
    Enhanced stimulation of antigen-specific immune responses against nucleophosmin 1 mutated acute myeloid leukaemia by an anti-programmed death 1 antibody.
    Br J Haematol. 2022;198:866-874.
    PubMed     Abstract available

  229. YEOH DK, Blyth CC, Kotecha RS
    Blinatumomab as bridging therapy in paediatric B-cell acute lymphoblastic leukaemia complicated by invasive fungal disease.
    Br J Haematol. 2022;198:887-892.
    PubMed     Abstract available

  230. ALBERTSEN BK, Lynggaard LS, Schmiegelow K
    Asparaginase encapsulated in erythrocytes as second-line treatment in hypersensitive patients with acute lymphoblastic leukaemia.
    Br J Haematol. 2022;198:e84-e85.

  231. BRECCIA M, Olimpieri PP, Celant S, Olimpieri O, et al
    Management of chronic myeloid leukaemia patients treated with ponatinib in a real-life setting: A retrospective analysis from the monitoring registries of the Italian Medicines Agency (AIFA).
    Br J Haematol. 2022;198:965-973.
    PubMed     Abstract available

  232. LI J, Liu L, Zhang R, Wan Y, et al
    Development and validation of a prognostic scoring model to risk stratify childhood acute myeloid leukaemia.
    Br J Haematol. 2022;198:1041-1050.
    PubMed     Abstract available

  233. VAN DER SLUIS IM, Bertrand Y, Baruchel A, Pieters R, et al
    Is asparaginase encapsulated in erythrocytes effective as second-line treatment in acute lymphoblastic leukaemia?
    Br J Haematol. 2022;198:e82-e83.

  234. MOGENSEN N, Saaranen E, Olsson E, Klug Albertsen B, et al
    Quality of life in mothers and fathers of children treated for acute lymphoblastic leukaemia in Sweden, Finland and Denmark.
    Br J Haematol. 2022;198:1032-1040.
    PubMed     Abstract available

  235. MOPPETT J
    Metabolomics: A biomarker to improve the assessment of central nervous system positive acute lymphoblastic leukaemia?
    Br J Haematol. 2022;198:939-940.

  236. TAYLOR GP, Cook LB
    A new paradigm for the management of ATL.
    Br J Haematol. 2022;198:941-942.

  237. FAVINI C, Talotta D, Almasri M, Andorno A, et al
    Clonally unrelated Richter syndrome are truly de novo diffuse large B-cell lymphomas with a mutational profile reminiscent of clonally related Richter syndrome.
    Br J Haematol. 2022;198:1016-1022.
    PubMed     Abstract available

  238. HARRINGTON P, Dillon R, Radia D, McLornan D, et al
    Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T-cell phenotype.
    Br J Haematol. 2022;198:1011-1015.
    PubMed     Abstract available

  239. SONG Z, Tang G, Zhuang C, Wang Y, et al
    Metabolomic profiling of cerebrospinal fluid reveals an early diagnostic model for central nervous system involvement in acute lymphoblastic leukaemia.
    Br J Haematol. 2022;198:994-1010.
    PubMed     Abstract available

    August 2022
  240. NAKHODA S, Vistarop A, Wang YL
    Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma.
    Br J Haematol. 2022 Aug 27. doi: 10.1111/bjh.18418.
    PubMed     Abstract available

  241. ISIDORI A, Loscocco F, Visani G, Paolasini S, et al
    Real-life efficacy and safety of idelalisib in 55 double-refractory follicular lymphoma patients.
    Br J Haematol. 2022 Aug 24. doi: 10.1111/bjh.18426.
    PubMed     Abstract available

  242. IMBERY JF, Heinzelbecker J, Jebsen JK, McGowan M, et al
    T-helper cell regulation of CD45 phosphatase activity by galectin-1 and CD43 governs chronic lymphocytic leukaemia proliferation.
    Br J Haematol. 2022;198:556-573.
    PubMed     Abstract available

  243. WANG X, Tang G, Hu Z, Fang H, et al
    Myeloid neoplasms with 8q24/MYC rearrangement are frequently associated with myelodysplasia, complex karyotype, TP53 alterations, and inferior survival.
    Br J Haematol. 2022;198:604-608.

  244. SANCHEZ-VIZCAINO F, Tamayo C, Ramos F, Lainez-Gonzalez D, et al
    Identification of seasonal variation in the diagnosis of acute myeloid leukaemia: a population-based study.
    Br J Haematol. 2022;198:545-555.
    PubMed     Abstract available

  245. LU L, Kok CH, Dang P, Branford S, et al
    Highly sensitive droplet digital polymerase chain reaction for BCR::ABL1 messenger RNA identifies patients with chronic myeloid leukaemia with a low probability of achieving treatment-free remission.
    Br J Haematol. 2022;198:600-603.

  246. PODVIN B, Guermouche H, Fournier E, Berthon C, et al
    Acute myeloid leukaemia with double minute chromosomes encompassing the 8q24 region.
    Br J Haematol. 2022;198:413.

  247. CHAN WY, Zhu C, Sanchez E, Gupta R, et al
    Antibody responses to SARS-CoV-2 vaccination in patients with acute myeloid leukaemia and high risk MDS on active anti-cancer therapies.
    Br J Haematol. 2022;198:478-481.

  248. HERAUDET L, Galtier J, Favre S, Peyraud F, et al
    VANDA regimen followed by blinatumomab leads to favourable outcome in patients with Philadelphia chromosome-negative B-precursor acute lymphoblastic leukaemia in first relapse.
    Br J Haematol. 2022;198:523-527.
    PubMed     Abstract available

  249. JAMY O, Lin K, Worth S, Bachiashvili K, et al
    Hypomethylating agent/venetoclax versus intensive chemotherapy in adults with relapsed or refractory acute myeloid leukaemia.
    Br J Haematol. 2022;198:e35-e37.

  250. ALHAJ ISSA Z, Altwijri A, Alfayez M
    Cerebral nocardiosis in ibrutinib-treated chronic lymphocytic leukaemia.
    Br J Haematol. 2022;198:414.

  251. ADES L, Duployez N, Guerci-Bresler A, Laribi K, et al
    A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations.
    Br J Haematol. 2022;198:535-544.
    PubMed     Abstract available

  252. RUSSELL NH, Hills RK, Kjeldsen L, Clark RE, et al
    A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial.
    Br J Haematol. 2022;198:528-534.
    PubMed     Abstract available

  253. VALTIS YK, Place AE, Silverman LB, Vrooman LM, et al
    Orthopaedic adverse events among adolescents and adults treated with asparaginase for acute lymphoblastic leukaemia.
    Br J Haematol. 2022;198:421-430.
    PubMed     Abstract available

  254. VOLPE VO, Al Ali N, Chan O, Padron E, et al
    Splicing factor 3B subunit 1 (SF3B1) mutation in the context of therapy-related myelodysplastic syndromes.
    Br J Haematol. 2022;198:713-720.
    PubMed     Abstract available

  255. MULLIGAN SP, Opat S, Marlton P, Kuss B, et al
    Ibrutinib use, treatment duration, and concomitant medications in Australian patients with relapsed or refractory chronic lymphocytic leukaemia.
    Br J Haematol. 2022;198:790-793.

  256. GENTHON A, Dragoi D, Memoli M, Hirsch P, et al
    Isocitrate dehydrogenase inhibitors as a bridge to allogeneic stem cell transplant in relapsed or refractory acute myeloid leukaemia.
    Br J Haematol. 2022;198:780-784.

  257. LAURA CS, Ana FM, Ines LH
    Pure erythroid leukaemia mimicking metastatic carcinoma.
    Br J Haematol. 2022;198:617.

    July 2022
  258. STRATI P, Coleman M, Champion R, Ma S, et al
    A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma.
    Br J Haematol. 2022 Jul 21. doi: 10.1111/bjh.18368.
    PubMed     Abstract available

  259. ROLDAN GALIACHO V, Zaldumbide Duenas L, Lobo Olmedo A, Alonso Varela M, et al
    Intracytoplasmic crystalline inclusions in peripheral blood lymphocytes in small lymphocytic lymphoma.
    Br J Haematol. 2022 Jul 21. doi: 10.1111/bjh.18380.

  260. MEYER LK, Delgado-Martin C, Sharp PP, Huang BJ, et al
    Inhibition of the Sec61 translocon overcomes cytokine-induced glucocorticoid resistance in T-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2022;198:137-141.
    PubMed     Abstract available

  261. GHANDILI S, Kluger MA, Leitner T, Grahammer F, et al
    Donor-transmitted extramedullary acute myeloid leukaemia after living donor kidney transplantation.
    Br J Haematol. 2022;198:199-202.

  262. KRIEL M, Opie J, Louw V, Musekwa E, et al
    Clover leaf nuclear morphology in chronic lymphocytic leukaemia with typical immunophenotype and absence of trisomy 12.
    Br J Haematol. 2022;198:8.

  263. PIMENTEL-VILLAR MA, Morales-Camacho RM, Vargas MT, Jimenez-Jambrina M, et al
    Erythrophagocytosis by blast cells in B-lymphoblastic leukaemia with BCR-ABL1.
    Br J Haematol. 2022;198:7.

    Beware clonal haematopoiesis following chronic lymphocytic leukaemia treatment.
    Br J Haematol. 2022;198:9-10.

  265. SIDHU J, Masurekar AN, Gogoi MP, Fong C, et al
    Activity and toxicity of intramuscular 1000 iu/m(2) polyethylene glycol-E. coli L-asparaginase in the UKALL 2003 and UKALL 2011 clinical trials.
    Br J Haematol. 2022;198:142-150.
    PubMed     Abstract available

  266. WANG J, Jiang H, Jing Y, Su L, et al
    Prognostic implications of the detection of measurable residual disease and mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA.
    Br J Haematol. 2022;198:e3-e8.

  267. VOSO MT, Pandzic T, Falconi G, Dencic-Fekete M, et al
    Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy.
    Br J Haematol. 2022;198:103-113.
    PubMed     Abstract available

  268. DE PROPRIS MS, Musiu P, Intoppa S, Nardacci MG, et al
    Hairy cell leukaemia with low CD103 expression: A rare but important diagnostic pitfall.
    Br J Haematol. 2022;198:e28-e31.

  269. STENGEL S, Petrie KR, Sbirkov Y, Stanko C, et al
    Suppression of MYC by PI3K/AKT/mTOR pathway inhibition in combination with all-trans retinoic acid treatment for therapeutic gain in acute myeloid leukaemia.
    Br J Haematol. 2022;198:338-348.
    PubMed     Abstract available

  270. DHUNPUTH C, Strullu M, Petit A, Merched M, et al
    Single-dose (4.5 mg/m(2) ) gemtuzumab ozogamicin in combination with fludarabine, cytarabine and anthracycline as reinduction therapy in relapsed or refractory paediatric acute myeloid leukaemia.
    Br J Haematol. 2022;198:373-381.
    PubMed     Abstract available

  271. SHIVAROV V, Grigorova D
    Dynamic trends in life expectancy and life years lost over five decades in patients from the SEER database with chronic myeloid leukaemia.
    Br J Haematol. 2022;198:e23-e25.

  272. GUO JJ, Cao L, Zhu HY, Miao Y, et al
    T-cell large granular lymphocytic leukaemia with atypical immunophenotypes: A single-centre retrospective analysis of 17 cases.
    Br J Haematol. 2022;198:e18-e22.

    June 2022
  273. KATAYAMA S, Hiraishi T, Ota M
    Skin manifestations of intravascular adult T-cell leukaemia/lymphoma.
    Br J Haematol. 2022 Jun 27. doi: 10.1111/bjh.18318.

  274. BRIVIO E, Cossio A, Borra D, Silvestri D, et al
    Osteonecrosis in paediatric acute lymphoblastic leukaemia: Incidence, risk factors, radiological patterns and evolution in a single-centre cohort.
    Br J Haematol. 2022;197:602-608.
    PubMed     Abstract available

  275. WALEWSKA R, Parry-Jones N, Eyre TA, Follows G, et al
    Guideline for the treatment of chronic lymphocytic leukaemia.
    Br J Haematol. 2022;197:544-557.

  276. MOIA R, Gaidano G
    Updated revision of the British Society of Haematology guidelines for chronic lymphocytic leukaemia.
    Br J Haematol. 2022;197:513-514.

  277. WANG QQ, Wang HF, Zhao JZ, Naranmandura H, et al
    Venetoclax for arsenic-resistant acute promyelocytic leukaemia.
    Br J Haematol. 2022;197:e58-e60.

  278. MERLI P
    Treating second-relapsed/refractory first-relapsed childhood acute myeloid leukaemia: Successful salvage rather than palliation?
    Br J Haematol. 2022;197:651-652.
    PubMed     Abstract available

  279. WANG M, Lin H, Chu X, Wang Z, et al
    Identification of a recurrent fusion NUP98-RARG in acute myeloid leukaemia resembling acute promyelocytic leukaemia.
    Br J Haematol. 2022;197:e73-e78.

  280. LYNGGAARD LS, Vaitkeviciene G, Langenskiold C, Lehmann AK, et al
    Asparaginase encapsulated in erythrocytes as second-line treatment in hypersensitive patients with acute lymphoblastic leukaemia.
    Br J Haematol. 2022;197:745-754.
    PubMed     Abstract available

  281. TARIQ H, Barnea Slonim L, Coty Fattal Z, Alikhan MB, et al
    Therapy-related myeloid neoplasms with normal karyotype show distinct genomic and clinical characteristics compared to their counterparts with abnormal karyotype.
    Br J Haematol. 2022;197:736-744.
    PubMed     Abstract available

  282. MORI A, Onozawa M, Tsukamoto S, Ishio T, et al
    Humoral response to mRNA-based COVID-19 vaccine in patients with myeloid malignancies.
    Br J Haematol. 2022;197:691-696.
    PubMed     Abstract available

  283. WHITE T, Kaspers G, Abrahamsson J, Arad-Cohen N, et al
    Clinical outcomes of second relapsed and refractory first relapsed paediatric AML: A retrospective study within the NOPHO-DB SHIP consortium.
    Br J Haematol. 2022;197:755-765.
    PubMed     Abstract available

    May 2022
  284. SHICHIJO T, Nosaka K, Tatetsu H, Higuchi Y, et al
    Beneficial impact of first-line mogamulizumab-containing chemotherapy in adult T-cell leukaemia-lymphoma.
    Br J Haematol. 2022 May 24. doi: 10.1111/bjh.18281.
    PubMed     Abstract available

  285. ZHU K, Jamroz A, Huang S, Villa D, et al
    Outcomes of Hodgkin variant Richter transformation in chronic lymphocytic leukaemia and small lymphocytic lymphoma in British Columbia.
    Br J Haematol. 2022 May 14. doi: 10.1111/bjh.18241.
    PubMed     Abstract available

  286. JOBSON D, McCormack CJ, Mar V, Tam C, et al
    Impact of chronic lymphocytic leukaemia on melanoma outcomes: A retrospective case-control study.
    Br J Haematol. 2022;197:320-325.
    PubMed     Abstract available

  287. TAYLOR T, Byrne J, Errico G, Clark D, et al
    Very late extramedullary relapse of acute myeloid leukaemia as prostatic myeloid sarcoma occurring 24 years post-allograft.
    Br J Haematol. 2022;197:243.

  288. OLIVEIRA AF, Tansini A, Toledo T, Balceiro R, et al

    Br J Haematol. 2022;197:339-348.
    PubMed     Abstract available

  289. UJJANI C, Shadman M, Lynch RC, Tu B, et al
    The impact of B-cell-directed therapy on SARS-CoV-2 vaccine efficacy in chronic lymphocytic leukaemia.
    Br J Haematol. 2022;197:306-309.
    PubMed     Abstract available

  290. CARTWRIGHT A, Scott S, Francis S, Whitby L, et al
    Assessing the impact of the 2017 European LeukemiaNet recommendations on FLT3 allelic ratio calculation and reporting in acute myeloid leukaemia.
    Br J Haematol. 2022;197:e35-e37.

  291. PETERSEN MA, Rosenberg CA, Brondum RF, Aggerholm A, et al
    Immunophenotypically defined stem cell subsets in paediatric AML are highly heterogeneous and demonstrate differences in BCL-2 expression by cytogenetic subgroups.
    Br J Haematol. 2022;197:452-466.
    PubMed     Abstract available

  292. WEI H, Zhou C, Liu B, Lin D, et al
    The prognostic factors in acute myeloid leukaemia with double-mutated CCAAT/enhancer-binding protein alpha (CEBPAdm).
    Br J Haematol. 2022;197:442-451.
    PubMed     Abstract available

  293. LEW TE, Anderson MA
    Health-related quality of life for patients with chronic lymphocytic leukaemia - A critical outcome measure in the era of highly effective therapies.
    Br J Haematol. 2022;197:394-396.

  294. OERLEMANS S, Efficace F, Kieffer JM, Kyriakou C, et al
    International validation of the EORTC QLQ-CLL17 questionnaire for assessment of health-related quality of life for patients with chronic lymphocytic leukaemia.
    Br J Haematol. 2022;197:431-441.
    PubMed     Abstract available

  295. JACOBY E, Bielorai B, Hutt D, Itzhaki O, et al
    Parameters of long-term response with CD28-based CD19 chimaeric antigen receptor-modified T cells in children and young adults with B-acute lymphoblastic leukaemia.
    Br J Haematol. 2022;197:475-481.
    PubMed     Abstract available

  296. ALTER BP, Giri N, McReynolds LJ, Altintas B, et al
    Fanconi anaemia: A syndrome with distinct subgroups.
    Br J Haematol. 2022;197:467-474.
    PubMed     Abstract available

  297. YU Q, Yu D, Chen X
    Cup-shaped nuclei in acute promyelocytic leukaemia.
    Br J Haematol. 2022;197:389.

    April 2022
  298. SUN C
    COVID-19 vaccine response in chronic lymphocytic leukaemia is more than just seroconversion.
    Br J Haematol. 2022;197:11-12.

  299. SHEN Y, Freeman JA, Holland J, Solterbeck A, et al
    COVID-19 vaccine failure in chronic lymphocytic leukaemia and monoclonal B-lymphocytosis; humoural and cellular immunity.
    Br J Haematol. 2022;197:41-51.
    PubMed     Abstract available

  300. CLAUDIANI S, Apperley JF, Parker EL, Marchesin F, et al
    Durable humoral responses after the second anti-SARS-CoV-2 vaccine dose in chronic myeloid leukaemia patients on tyrosine kinase inhibitors.
    Br J Haematol. 2022;197:e1-e4.

  301. ON S, Rath CG, Lan M, Wu B, et al
    Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent.
    Br J Haematol. 2022;197:63-70.
    PubMed     Abstract available

  302. GADI D, Griffith A, Wang Z, Tyekucheva S, et al
    Idelalisib reduces regulatory T cells and activates T helper 17 cell differentiation in relapsed refractory patients with chronic lymphocytic leukaemia.
    Br J Haematol. 2022;197:207-211.
    PubMed     Abstract available

  303. RECKZEH K, Estruch M, Ali M, Sogaard Helbo A, et al
    TET2 deficiency cooperates with CBFB-MYH11 to induce acute myeloid leukaemia and represents an early leukaemogenic event.
    Br J Haematol. 2022;197:201-206.

    BCR::ABL1 transcripts and clinical outcome - interrogating the technique.
    Br J Haematol. 2022;197:9-10.

  305. DOMINY KM, Claudiani S, O'Hare M, Szydlo R, et al
    Assessment of quantitative polymerase chain reaction for BCR-ABL1 transcripts in chronic myeloid leukaemia: Are improved outcomes in patients with e14a2 transcripts an artefact of technology?
    Br J Haematol. 2022;197:52-62.
    PubMed     Abstract available

  306. VERBEEK MWC, Buracchi C, Laqua A, Nierkens S, et al
    Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies - a EuroFlow study.
    Br J Haematol. 2022;197:76-81.
    PubMed     Abstract available

  307. HILLS RK
    Historical controls and venous thromboembolism prophylaxis in acute lymphoblastic leukaemia: things can only get better?
    Br J Haematol. 2022;197:e26-e27.

  308. YEUNG DTO, Osborn MP, White DL
    B-cell acute lymphoblastic leukaemia: recent discoveries in molecular pathology, their prognostic significance, and a review of the current classification.
    Br J Haematol. 2022;197:13-27.
    PubMed     Abstract available

  309. TONG WH
    Does anticoagulation prophylaxis reduce the rate of venous thromboembolism in adult acute lymphoblastic leukaemia treated with asparaginase-based therapy?
    Br J Haematol. 2022;197:e24-e25.

  310. JENSEN K, Oskarsson T, Lahteenmaki P, Flaegstad T, et al
    Doing less, accomplishing more for childhood ALL: response.
    Br J Haematol. 2022;197:120.

    March 2022
  311. CULL G, Burger JA, Opat S, Gottlieb D, et al
    Zanubrutinib for treatment-naive and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study.
    Br J Haematol. 2022;196:1209-1218.
    PubMed     Abstract available

  312. MORIYA K, Imamura T, Katayama S, Kaino A, et al
    The incidence of symptomatic osteonecrosis is similar between Japanese children and children in Western countries with acute lymphoblastic leukaemia treated with a Berlin-Frankfurt-Munster (BFM)95-based protocol.
    Br J Haematol. 2022;196:1257-1261.
    PubMed     Abstract available

  313. MAAS CCHM, van Klaveren D, Ector GICG, Posthuma EFM, et al
    The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population-based study in the Netherlands, 1989-2018.
    Br J Haematol. 2022;196:1219-1224.
    PubMed     Abstract available

  314. BARZILAI-BIRENBOIM S, Elitzur S, Nirel R, Ehrenberg M, et al
    Elevated intraocular pressure in children with acute lymphoblastic leukaemia: A prospective study.
    Br J Haematol. 2022;196:1248-1256.
    PubMed     Abstract available

  315. DILLON R, Hills RK, Burnett AK, Russell NH, et al
    Gemtuzumab ozogamicin in (KMT2A)-rearranged adult acute myeloid leukaemia (AML) in the UK Medical Research Council AML15 and AML16 trials.
    Br J Haematol. 2022;196:e50-e52.

  316. WALDRON C, O'Brien D, Brophy S, Perera K, et al
    Epidemiology of chronic lymphocytic leukaemia in an Irish subpopulation with total case ascertainment: an additional tool for health economic planning.
    Br J Haematol. 2022;196:e47-e49.

  317. EGNELL C, Heyman M, Jonsson OG, Raja RA, et al
    Obesity as a predictor of treatment-related toxicity in children with acute lymphoblastic leukaemia.
    Br J Haematol. 2022;196:1239-1247.
    PubMed     Abstract available

  318. GALLIPOLI P, Clark RE, Byrne J, Apperley JF, et al
    The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukaemia.
    Br J Haematol. 2022;196:e55-e57.

  319. COATS T, Bean D, Basset A, Sirkis T, et al
    A novel algorithmic approach to generate consensus treatment guidelines in adult acute myeloid leukaemia.
    Br J Haematol. 2022;196:1337-1343.
    PubMed     Abstract available

  320. SALHOTRA A, Tsai NC, Zhang J, Ngo D, et al
    Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia.
    Br J Haematol. 2022;196:e71-e74.

  321. RUSSELL N, Hills R, Kjeldsen L, Dennis M, et al
    Treatment intensification with FLAG-Ida may improve disease control in younger patients with secondary acute myeloid leukaemia: long-term follow up of the MRC AML15 trial.
    Br J Haematol. 2022;196:1344-1347.
    PubMed     Abstract available

  322. MCCLURE BJ, Pal M, Heatley SL, Rehn J, et al
    Two novel cases of NUTM1-rearranged B-cell acute lymphoblastic leukaemia presenting with high-risk features.
    Br J Haematol. 2022;196:1407-1411.

  323. LINCH DC, Hills RK, Burnett AK, Russell N, et al
    Therapy for isocitrate dehydrogenase 2 (IDH2)(R172) -mutant acute myeloid leukaemia.
    Br J Haematol. 2022;196:1348-1352.
    PubMed     Abstract available

  324. BENDE RJ, Janssen J, van Noesel CJM
    Higher-order of chronic lymphocytic leukaemia (CLL) classification: shared antigenic specificities of stereotyped B-cell receptor subsets as defined by the European Research Initiative on CLL consortium.
    Br J Haematol. 2022;196:e60-e63.

  325. TAWANA K, Brown AL, Churpek JE
    Integrating germline variant assessment into routine clinical practice for myelodysplastic syndrome and acute myeloid leukaemia: current strategies and challenges.
    Br J Haematol. 2022;196:1293-1310.
    PubMed     Abstract available

    February 2022
    Is COVID-19 less severe in CML patients than in those with other haematological cancers?
    Br J Haematol. 2022;196:471-472.

  327. BRECCIA M, Abruzzese E, Accurso V, Attolico I, et al
    COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report.
    Br J Haematol. 2022;196:559-565.
    PubMed     Abstract available

  328. SCHENKER C, Hirzel C, Walti LN, Zeerleder SS, et al
    Convalescent plasma and remdesivir for protracted COVID-19 in a patient with chronic lymphocytic leukaemia: a case report of late relapse after rapid initial response.
    Br J Haematol. 2022;196:e27-e29.

  329. BIONDI A, Conter V, Chandy M, Ewald P, et al
    Precursor B-cell acute lymphoblastic leukaemia-a global view.
    Br J Haematol. 2022;196:530-547.
    PubMed     Abstract available

  330. SALEK C, Folber F, Fronkova E, Pecherkova P, et al
    Low levels of minimal residual disease after induction chemotherapy for BCR-ABL1-negative acute lymphoblastic leukaemia in adults are clinically relevant.
    Br J Haematol. 2022;196:706-710.
    PubMed     Abstract available

  331. DOWNES CEJ, Rehn J, Heatley SL, Yeung D, et al
    Identification of a novel GOLGA4-JAK2 fusion gene in B-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2022;196:700-705.
    PubMed     Abstract available

  332. SCHWAB CJ, Murdy D, Butler E, Enshaei A, et al
    Genetic characterisation of childhood B-other-acute lymphoblastic leukaemia in UK patients by fluorescence in situ hybridisation and Multiplex Ligation-dependent Probe Amplification.
    Br J Haematol. 2022;196:753-763.
    PubMed     Abstract available

  333. TANDON S, Visser R, Astwood E, Payne J, et al
    Paediatric ambiguous lineage leukaemia with monocytic differentiation at diagnosis: case series and review of literature.
    Br J Haematol. 2022;196:e34-e39.

  334. KRIEG S, Seeger H, Hofmann P, Del Prete C, et al
    Baseline creatinine predicts acute kidney injury during intensive therapy in transplant-eligible patients with acute myeloid leukaemia.
    Br J Haematol. 2022;196:781-784.

  335. VOJDEMAN FJ, Helby J, Pedersen LB, Brieghel C, et al
    Chronic lymphocytic leukaemia clones are detectable decades before diagnosis.
    Br J Haematol. 2022;196:784-787.

  336. HUANG W, Sundquist K, Sundquist J, Ji J, et al
    Use of dipyridamole is associated with lower risk of lymphoid neoplasms: a propensity score-matched cohort study.
    Br J Haematol. 2022;196:690-699.
    PubMed     Abstract available

  337. RIBERA J, Granada I, Morgades M, Gonzalez T, et al
    Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols.
    Br J Haematol. 2022;196:670-675.
    PubMed     Abstract available

  338. BOOTH S, Curley HM, Varnai C, Arnold R, et al
    Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19: disease control as an important factor relative to recent chemotherapy or anti-CD20 therapy.
    Br J Haematol. 2022;196:892-901.
    PubMed     Abstract available

  339. ALLAN JN, Shanafelt T, Wiestner A, Moreno C, et al
    Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
    Br J Haematol. 2022;196:947-953.
    PubMed     Abstract available

  340. AHMED HMM, Nimmagadda SC, Al-Matary YS, Fiori M, et al
    Dexamethasone-mediated inhibition of Notch signalling blocks the interaction of leukaemia and mesenchymal stromal cells.
    Br J Haematol. 2022;196:995-1006.
    PubMed     Abstract available

  341. SHEN Z, Zhou M, Zhang J, Chen S, et al
    Microgranular variant of acute promyelocytic leukaemia with an unusual T/myeloid immunophenotype resembling that of mixed-phenotype acute leukaemia.
    Br J Haematol. 2022;196:801.

  342. ABDEL RAHMAN ZH, Parrondo RD, Heckman MG, Wieczorek M, et al
    Comparative study of therapy-related and de novo adult b-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2022;196:963-968.
    PubMed     Abstract available

  343. EYRE TA, Riches JC, Patten PEM, Walewska R, et al
    Richter transformation of chronic lymphocytic leukaemia: a British Society for Haematology Good Practice Paper.
    Br J Haematol. 2022;196:864-870.

    January 2022
  344. TOMOWIAK C, Leblond V, Laribi K, Baron M, et al
    Response to vaccination against SARS-CoV-2 in 168 patients with Waldenstrom macroglobulinemia: a French Innovative Leukemia Organization (FILO) study.
    Br J Haematol. 2022 Jan 14. doi: 10.1111/bjh.18055.

  345. NAVILLE AS, Lazaro E, Boutin J, Prot-Leurent C, et al
    Acquired glucose 6-phosphate dehydrogenase (G6PD) deficiency in a patient with Chronic Myelomonocytic Leukemia.
    Br J Haematol. 2022 Jan 6. doi: 10.1111/bjh.18037.

  346. SAULTIER P, Ninove L, Szepetowski S, Veneziano M, et al
    Monoclonal antibodies for the treatment of COVID-19 in a patient with high-risk acute leukaemia.
    Br J Haematol. 2022;196:e1-e3.

  347. MARCHESI F, Pimpinelli F, Sperandio E, Papa E, et al
    The 12-week kinetics of anti-SARS-CoV-2 antibodies in different haematological cancers after vaccination with BNT162b2.
    Br J Haematol. 2022;196:362-367.

  348. GASTINNE T, Le Bourgeois A, Coste-Burel M, Guillaume T, et al
    Safety and antibody response after one and/or two doses of BNT162b2 Anti-SARS-CoV-2 mRNA vaccine in patients treated by CAR T cells therapy.
    Br J Haematol. 2022;196:360-362.

  349. SEVIAR D, Nyunt K, Sayer C, Wright D, et al
    Romboutsia-induced bone marrow necrosis at presentation of acute myeloid leukaemia.
    Br J Haematol. 2022;196:262.

  350. YAO H, Huo L, Ping N, Liu H, et al
    Recurrent mutations in multiple components of the SWI/SNF complex in myelodysplastic syndromes and acute myeloid leukaemia.
    Br J Haematol. 2022;196:441-444.

  351. KIM DDH, Kim TS, Atenafu EG, Novitzky Basso I, et al
    BCR-ABL1 transcript doubling time as a predictor for treatment-free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase.
    Br J Haematol. 2022;196:136-145.
    PubMed     Abstract available

  352. LOKE J, Metzner M, Boucher R, Jackson A, et al
    Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapy.
    Br J Haematol. 2022;196:368-373.
    PubMed     Abstract available

  353. PODVIN B, Goursaud L, Roynard P, Nibourel O, et al
    Chronic myeloid leukaemia presenting with monocytosis.
    Br J Haematol. 2022;196:8.

  354. NAKAJIMA R, Matsuo T, Sumiyoshi R, Saito S, et al
    Extramedullary blast crisis in a chronic myeloid leukaemia patient after achieving a major molecular response with bosutinib.
    Br J Haematol. 2022;196:e9-e11.

  355. KAYSER S, Levis MJ
    Updates on targeted therapies for acute myeloid leukaemia.
    Br J Haematol. 2022;196:316-328.
    PubMed     Abstract available

  356. MIKHAILOVA E, Roumiantseva J, Illarionova O, Lagoyko S, et al
    Strong expansion of normal CD19-negative B-cell precursors after the use of blinatumomab in the first-line therapy of acute lymphoblastic leukaemia in children.
    Br J Haematol. 2022;196:e6-e9.

  357. SHANMUGANATHAN N, Branford S
    Multiplex technologies for the assessment of minimal residual disease and low-level mutation detection in leukaemia: mass spectrometry versus next-generation sequencing.
    Br J Haematol. 2022;196:19-30.
    PubMed     Abstract available

    December 2021
  358. FOX TA, Kirkwood AA, Enfield L, O'Reilly M, et al
    Low seropositivity and suboptimal neutralisation rates in patients fully vaccinated against COVID-19 with B-cell malignancies.
    Br J Haematol. 2021;195:706-709.

  359. KIM HS, Lee JW, Kang D, Yu H, et al
    Characteristics of RAS pathway mutations in juvenile myelomonocytic leukaemia: a single-institution study from Korea.
    Br J Haematol. 2021;195:748-756.
    PubMed     Abstract available

  360. MINGUELA A, Salido EJ, Soto-Ramirez MF, Olga MA, et al
    Low-affinity immunoglobulin gamma Fc region receptor III-B (FcgammaRIIIB, CD16B) deficiency in patients with blood and immune system disorders.
    Br J Haematol. 2021;195:743-747.
    PubMed     Abstract available

  361. SILLA L, Valim V, Pezzi A, da Silva M, et al
    Adoptive immunotherapy with double-bright (CD56(bright) /CD16(bright) ) expanded natural killer cells in patients with relapsed or refractory acute myeloid leukaemia: a proof-of-concept study.
    Br J Haematol. 2021;195:710-721.
    PubMed     Abstract available

  362. TANG FF, Lu SY, Zhao XS, Qin YZ, et al
    PML-RARA transcript levels at the end of induction therapy are associated with prognosis in non-high-risk acute promyelocytic leukaemia with all-trans retinoic acid plus arsenic in front-line therapy: long-term follow-up of a single-centre cohort stud
    Br J Haematol. 2021;195:722-730.
    PubMed     Abstract available

    November 2021
  363. FOX CP, Ahearne MJ, Pettengell R, Dearden C, et al
    Guidelines for the management of mature T- and natural killer-cell lymphomas (excluding cutaneous T-cell lymphoma): a British Society for Haematology Guideline.
    Br J Haematol. 2021 Nov 22. doi: 10.1111/bjh.17951.

  364. BENDA M, Mutschlechner B, Ulmer H, Grabher C, et al
    Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients.
    Br J Haematol. 2021;195:523-531.
    PubMed     Abstract available

  365. SHIMONI A, Robin M, Iacobelli S, Beelen D, et al
    Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT.
    Br J Haematol. 2021;195:417-428.
    PubMed     Abstract available

  366. HWANG J, Singh N, Braniecki M, Gok Yavuz B, et al
    Omacetaxine added to a standard acute myeloid leukaemia chemotherapy regimen reduces cellular FLIP levels, markedly increasing the incidence of eccrine hidradenitis.
    Br J Haematol. 2021;195:e138-e141.

  367. SMYTH L, Blunt DN, Cheung MC
    Statins in mature B-cell lymphomas and leukaemias.
    Br J Haematol. 2021;195:490-492.

  368. SOLANO DE LA ASUNCION C, Terol MJ, Saus A, Olea B, et al
    Cytomegalovirus-specific T-cell immunity and DNAemia in patients with chronic lymphocytic leukaemia undergoing treatment with ibrutinib.
    Br J Haematol. 2021;195:637-641.

  369. BEGNA KH, Kittur J, Yui J, Gangat N, et al
    De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases.
    Br J Haematol. 2021;195:413-416.
    PubMed     Abstract available

  370. ZHONG ZQ, Zhuang HF, Wu SL, Zhang H, et al
    Pseudo-Chediak-Higashi inclusions in relapsed acute lymphoblastic leukaemia.
    Br J Haematol. 2021;195:300.

  371. SKOU AS, Juul-Dam KL, Ommen HB, Hasle H, et al
    Peripheral blood molecular measurable residual disease is sufficient to identify patients with acute myeloid leukaemia with imminent clinical relapse.
    Br J Haematol. 2021;195:310-327.
    PubMed     Abstract available

    October 2021
  372. NOSAKA K, Kusumoto S, Nakano N, Choi I, et al
    Clinical significance of the immunoglobulin G heavy-chain repertoire in peripheral blood mononuclear cells of adult T-cell leukaemia-lymphoma patients receiving mogamulizumab.
    Br J Haematol. 2021 Oct 10. doi: 10.1111/bjh.17895.
    PubMed     Abstract available

  373. LIU M, Zhao X, Pan W, Qian Z, et al
    A novel HNRNPC-RARA fusion in acute promyelocytic leukaemia lacking PML-RARA rearrangement, sensitive to venetoclax-based therapy.
    Br J Haematol. 2021;195:e123-e128.

  374. BARTRAM J, Balasch-Carulla M, Bhojaraja S, Adams S, et al
    Blinatumomab for paediatric mixed phenotype acute leukaemia.
    Br J Haematol. 2021;195:289-292.

  375. EDWARDS K, Zaitseva K, Sayed U, Volpi EV, et al
    Expression patterns of CD180 in the lymph nodes of patients with chronic lymphocytic leukaemia.
    Br J Haematol. 2021;195:e131-e134.

  376. TESTI AM, Mohamed S, Diverio D, Piciocchi A, et al
    Outcome of relapsed/refractory acute promyelocytic leukaemia in children, adolescents and young adult patients - a 25-year Italian experience.
    Br J Haematol. 2021;195:278-283.

  377. BEZDEKOVA R, Jelinek T, Kralova R, Stork M, et al
    Necessity of flow cytometry assessment of circulating plasma cells and its connection with clinical characteristics of primary and secondary plasma cell leukaemia.
    Br J Haematol. 2021;195:95-107.
    PubMed     Abstract available

  378. GOULD C, Lickiss J, Kankanige Y, Yerneni S, et al
    Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic target.
    Br J Haematol. 2021;195:113-118.
    PubMed     Abstract available

  379. THASTRUP M, Marquart HV, Levinsen M, Modvig S, et al
    Flow cytometric analysis of cerebrospinal fluid improves detection of leukaemic blasts in infants with acute lymphoblastic leukaemia.
    Br J Haematol. 2021;195:119-122.
    PubMed     Abstract available

  380. O'CONNOR D, Loke J, Brown M, Stanworth SJ, et al
    Non-pharmacological supportive-care interventions in acute myeloid leukaemia: a review of randomised controlled trials.
    Br J Haematol. 2021;195:e97-e113.

  381. MAENG CV, Ostgard LSG, Christiansen CF, Liu KD, et al
    Changes in intensive care unit admission rates, organ support, and mortality in patients with acute myeloid leukaemia over a 12-year period: a Danish nationwide cohort study.
    Br J Haematol. 2021;195:137-140.

    September 2021
  382. COOK LBM
    Adult T-cell leukaemia/lymphoma and the trouble with TP53.
    Br J Haematol. 2021 Sep 9. doi: 10.1111/bjh.17830.

  383. CHATTERJEE G, Sriram H, Ghogale S, Deshpande N, et al
    Mimics and artefacts of measurable residual disease in a highly sensitive multicolour flow cytometry assay for B-lymphoblastic leukaemia/lymphoma: critical consideration for analysis of measurable residual disease.
    Br J Haematol. 2021 Sep 2. doi: 10.1111/bjh.17801.
    PubMed     Abstract available

  384. CHOWDHURY O, Bruguier H, Mallett G, Sousos N, et al
    Impaired antibody response to COVID-19 vaccination in patients with chronic myeloid neoplasms.
    Br J Haematol. 2021;194:1010-1015.

  385. HARRINGTON P, Doores KJ, Radia D, O'Reilly A, et al
    Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia.
    Br J Haematol. 2021;194:999-1006.
    PubMed     Abstract available

  386. A special issue on modern genomics in diagnostic haematology.
    Br J Haematol. 2021;194:801-802.

  387. KUIPER RP, Hoogeveen PG, Bladergroen R, van Dijk F, et al
    Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all.
    Br J Haematol. 2021;194:888-892.
    PubMed     Abstract available

  388. KHAN M, Roddy JT, Hernandez JR, Bursch K, et al
    Revisiting biochemistry: severe euglycemic ketoacidosis in the setting of IDH-inhibitor therapy for AML.
    Br J Haematol. 2021;194:1083-1085.

  389. RASCHE A, Mason EF, Strickland SA, Byrne M, et al
    Isocitrate dehydrogenase inhibitor-driven differentiation may resemble secondary graft failure in post-allogeneic haematopoietic cell transplantation relapsed acute myeloid leukaemia.
    Br J Haematol. 2021;194:927-931.

  390. ALCALDE-MELLADO P, Franco-Macias E, Morales-Camacho RM, Caballero-Velazquez T, et al
    Auer rod-like inclusions in cerebrospinal fluid in accelerated phase chronic lymphocytic leukaemia.
    Br J Haematol. 2021;194:946.

    August 2021
  391. SAKAMOTO Y, Ishida T, Masaki A, Murase T, et al
    Clinical significance of TP53 mutations in adult T-cell leukemia/lymphoma.
    Br J Haematol. 2021 Aug 17. doi: 10.1111/bjh.17749.
    PubMed     Abstract available

  392. FANG H, Wang W, El Hussein S, Morita K, et al
    B-cell lymphoma/leukaemia 11B (BCL11B) expression status helps distinguish early T-cell precursor acute lymphoblastic leukaemia/lymphoma (ETP-ALL/LBL) from other subtypes of T-cell ALL/LBL.
    Br J Haematol. 2021 Aug 16. doi: 10.1111/bjh.17681.
    PubMed     Abstract available

  393. HENRY A, Bracquemart C, Naguib D, Chantepie S, et al
    Does eventually NPM1 mutation in blast phase chronic myeloid leukemia (BP-CML) exist? That is the question.
    Br J Haematol. 2021 Aug 15. doi: 10.1111/bjh.17761.

  394. PATEL PA, Lapp SA, Grubbs G, Edara VV, et al
    Immune responses and therapeutic challenges in paediatric patients with new-onset acute myeloid leukaemia and concomitant COVID-19.
    Br J Haematol. 2021;194:549-553.

  395. LUCCHINI G, Furness C, Lawson S, Gibson B, et al
    COVID-19 infection in paediatric recipients of allogeneic stem cell transplantation: the UK experience.
    Br J Haematol. 2021;194:e74-e77.

  396. YEOH AEJ, Oh BL, Ariffin H
    Doing less, accomplishing more for childhood acute lymphoblastic leukaemia (ALL).
    Br J Haematol. 2021;194:661-662.

  397. NOURA M, Morita K, Kiyose H, Okuno Y, et al
    Albendazole induces the terminal differentiation of acute myeloid leukaemia cells to monocytes by stimulating the Kruppel-like factor 4-dihydropyrimidinase-like 2A (KLF4-DPYSL2A) axis.
    Br J Haematol. 2021;194:598-603.
    PubMed     Abstract available

  398. RAMDENY PS, Mullanfroze K, de Lorenzo P, Grazia Valsecchi M, et al
    Infant T-cell acute lymphoblastic leukaemia with t(6;7) (TCRB-MYB) translocation.
    Br J Haematol. 2021;194:613-616.
    PubMed     Abstract available

  399. ROMZOVA M, Smitalova D, Hynst J, Tom N, et al
    Hierarchical distribution of somatic variants in newly diagnosed chronic myeloid leukaemia at diagnosis and early follow-up.
    Br J Haematol. 2021;194:604-612.
    PubMed     Abstract available

  400. MASLAH N, Diawara Y, Sebert M, Giraudier S, et al
    In vitro assessment of the sensitivity to APR-246 + azacitidine combination predicts response to this combination in myelodysplastic/acute myeloid leukaemia patients.
    Br J Haematol. 2021;194:e77-e79.

  401. JENSEN KS, Oskarsson T, Lahteenmaki PM, Flaegstad T, et al
    Detection mode of childhood acute lymphoblastic leukaemia relapse and its effect on survival: a Nordic population-based cohort study.
    Br J Haematol. 2021;194:734-744.
    PubMed     Abstract available

  402. CORNEAU A, Parizot C, Cherai M, Todesco E, et al
    Mass Cytometry: a robust platform for the comprehensive immunomonitoring of CAR-T-cell therapies.
    Br J Haematol. 2021;194:788-792.

  403. ALLSUP D, Howard D, Emmerson J, Hockaday A, et al
    COSMIC, chemotherapy plus ofatumumab at standard or mega-dose in chronic lymphocytic leukaemia, a phase II randomised study.
    Br J Haematol. 2021;194:646-650.

  404. LOBO-OLMEDO A, Roldan Galiacho V, Arzuaga-Mendez J, Ancin I, et al
    Acute megakaryoblastic leukaemia with erythrophagocytosis.
    Br J Haematol. 2021;194:658.

    July 2021
  405. BRANVALL E, Ekberg S, Eloranta S, Wasterlid T, et al
    Statin use and survival in 16 098 patients with non-Hodgkin lymphoma or chronic lymphocytic leukaemia treated in the rituximab era.
    Br J Haematol. 2021 Jul 31. doi: 10.1111/bjh.17733.
    PubMed     Abstract available

  406. MOIA R, Favini C, Ferri V, Forestieri G, et al
    Multiregional sequencing and circulating tumour DNA analysis provide complementary approaches for comprehensive disease profiling of small lymphocytic lymphoma.
    Br J Haematol. 2021 Jul 22. doi: 10.1111/bjh.17718.
    PubMed     Abstract available

    What is the right dosage of dasatinib for treating chronic myeloid leukaemia?
    Br J Haematol. 2021;194:234.

  408. ROUSSELOT P, Mollica L, Guilhot J, Guerci A, et al
    Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients.
    Br J Haematol. 2021;194:393-402.
    PubMed     Abstract available

  409. NAKAMURA M, Arai Y, Hirabayashi S, Kondo T, et al
    Residual disease is a strong prognostic marker in patients with acute lymphoblastic leukaemia with chemotherapy-refractory or relapsed disease prior to allogeneic stem cell transplantation.
    Br J Haematol. 2021;194:403-413.
    PubMed     Abstract available

  410. COMONT T, Meunier M, Cherait A, Santana C, et al
    Eltrombopag for myelodysplastic syndromes or chronic myelomonocytic leukaemia with no excess blasts and thrombocytopenia: a French multicentre retrospective real-life study.
    Br J Haematol. 2021;194:336-343.
    PubMed     Abstract available

  411. WIERNIK PH, Sun Z, Cripe LD, Rowe JM, et al
    Prognostic effect of gender on outcome of treatment for adults with acute myeloid leukaemia.
    Br J Haematol. 2021;194:309-318.
    PubMed     Abstract available

  412. ROEKER LE, Thompson MC, Mato AR
    Searching for a home: phosphoinositide 3-kinase inhibitors for chronic lymphocytic leukaemia in modern clinical practice.
    Br J Haematol. 2021;194:9-10.

  413. MULRONEY CM, Abid MB, Bashey A, Chemaly RF, et al
    Incidence and impact of community respiratory viral infections in post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical stem cell transplantation.
    Br J Haematol. 2021;194:145-157.
    PubMed     Abstract available

  414. EYRE TA, Preston G, Kagdi H, Islam A, et al
    A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO-idel).
    Br J Haematol. 2021;194:69-77.
    PubMed     Abstract available

  415. SASAKI K, Tsujimoto S, Miyake M, Uchiyama Y, et al
    Droplet digital polymerase chain reaction assay for the detection of the minor clone of KIT D816V in paediatric acute myeloid leukaemia especially showing RUNX1-RUNX1T1 transcripts.
    Br J Haematol. 2021;194:414-422.
    PubMed     Abstract available

  416. SCOTT S, Cartwright A, Francis S, Whitby L, et al
    Assessment of droplet digital polymerase chain reaction for measuring BCR-ABL1 in chronic myeloid leukaemia in an international interlaboratory study.
    Br J Haematol. 2021;194:53-60.
    PubMed     Abstract available

  417. RADICH J
    Building a better mousetrap for accurate and sensitive polymerase chain reaction.
    Br J Haematol. 2021;194:11-13.

  418. SASSEN SDT, Mathot RAA, Pieters R, de Haas V, et al
    Evaluation of the pharmacokinetics of prednisolone in paediatric patients with acute lymphoblastic leukaemia treated according to Dutch Childhood Oncology Group protocols and its relation to treatment response.
    Br J Haematol. 2021;194:423-432.
    PubMed     Abstract available

  419. KOUKOULIAS K, Papadopoulou A, Kouimtzidis A, Papayanni PG, et al
    Non-transplantable cord blood units as a source for adoptive immunotherapy of leukaemia and a paradigm of circular economy in medicine.
    Br J Haematol. 2021;194:158-167.
    PubMed     Abstract available

  420. BODOR C, Kotmayer L, Laszlo T, Takacs F, et al
    Screening and monitoring of the BTK(C481S) mutation in a real-world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy.
    Br J Haematol. 2021;194:355-364.
    PubMed     Abstract available

  421. MICHALOWSKI MB, Cecconello DK, Lins MM, Carvalho MDPSS, et al
    Influence of different asparaginase formulations in the prognosis of children with acute lymphocytic leukaemia in Brazil: a multicentre, retrospective controlled study.
    Br J Haematol. 2021;194:168-173.
    PubMed     Abstract available

  422. ZHAO Y, McCracken J, Rehder C, Wang E, et al
    Biclonal evolution of chronic lymphocytic leukaemia.
    Br J Haematol. 2021;194:e64-e66.

  423. CHERNG HJ, Jammal N, Paul S, Wang X, et al
    Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia.
    Br J Haematol. 2021;194:61-68.
    PubMed     Abstract available

  424. DENNIS M, Burnett A, Hills R, Thomas I, et al
    A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial.
    Br J Haematol. 2021;194:298-308.
    PubMed     Abstract available

  425. POCOCK R, Farah N, Richardson SE, Mansour MR, et al
    Current and emerging therapeutic approaches for T-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2021;194:28-43.
    PubMed     Abstract available

  426. ASSANTO GM, Riemma C, Malaspina F, Perrone S, et al
    The current role of interferon in hairy cell leukaemia: clinical and molecular aspects.
    Br J Haematol. 2021;194:78-82.
    PubMed     Abstract available

  427. POPOV A, Fominikh V, Mikhailova E, Shelikhova L, et al
    Blinatumomab following haematopoietic stem cell transplantation - a novel approach for the treatment of acute lymphoblastic leukaemia in infants.
    Br J Haematol. 2021;194:174-178.
    PubMed     Abstract available

  428. KOLLA BC, Halim NAA, Cao Q, Sachs Z, et al
    High risk of relapse with intermediate dose cytarabine for consolidation in young favourable-risk acute myeloid leukaemia patients following induction with 7+3: a retrospective multicentre analysis and critical review of the literature.
    Br J Haematol. 2021;194:140-144.
    PubMed     Abstract available

  429. HSU H, Roncolato F, Lee SH
    Lysosomal acid lipase deficiency diagnosed in a patient presenting with acute myeloid leukaemia.
    Br J Haematol. 2021;194:228.

  430. SHACKLETON L, McCarthy J, Mykytiv V
    Extramedullary pericardial haematopoiesis as a presenting feature of chronic myeloid leukaemia.
    Br J Haematol. 2021;194:7.

    June 2021
  431. OSTERGAARD J, Jonart LM, Ebadi M, Koppenhafer SL, et al
    Preclinical efficacy of prexasertib in acute lymphoblastic leukemia.
    Br J Haematol. 2021 Jun 7. doi: 10.1111/bjh.17610.

  432. KARANTANOS T, Gondek LP, Varadhan R, Moliterno AR, et al
    Gender-related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
    Br J Haematol. 2021;193:1142-1150.
    PubMed     Abstract available

  433. XU R, Huang X, Li C, Deng C, et al
    Bone marrow mesenchymal stromal cells in chronic myelomonocytic leukaemia: overactivated WNT/beta-catenin signalling by parallel RNA sequencing and dysfunctional phenotypes.
    Br J Haematol. 2021;193:928-940.
    PubMed     Abstract available

  434. MOSKORZ W, Cosmovici C, Jager PS, Cadeddu RP, et al
    Myelodysplastic syndrome patients display alterations in their immune status reflected by increased PD-L1-expressing stem cells and highly dynamic exhausted T-cell frequencies.
    Br J Haematol. 2021;193:941-945.
    PubMed     Abstract available

  435. CAO H, Neerincx A, de Bono B, Lakner U, et al
    Sialic acid-binding immunoglobulin-like lectin (Sigelac)-15 is a rapidly internalised cell-surface antigen expressed by acute myeloid leukaemia cells.
    Br J Haematol. 2021;193:946-950.
    PubMed     Abstract available

  436. DHOLARIA B, Savani BN, Huang XJ, Nagler A, et al
    The evolving role of allogeneic haematopoietic cell transplantation in the era of chimaeric antigen receptor T-cell therapy.
    Br J Haematol. 2021;193:1060-1075.
    PubMed     Abstract available

  437. NISHIMURA A, Naruto T, Miyamoto S, Grigg A, et al
    Genomics analysis of leukaemia predisposition in X-linked agammaglobulinaemia.
    Br J Haematol. 2021;193:1277-1281.

  438. VAN DE GEER A, Zandstra J, Tanck MWT, Nur E, et al
    Biomarkers to predict infection and infection-related complications during chemotherapy-induced neutropenia in acute myeloid leukaemia: a pilot study.
    Br J Haematol. 2021;193:1008-1012.

  439. SHAH MV, Saliba RM, Varma A, Ciurea SO, et al
    Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era.
    Br J Haematol. 2021;193:1004-1008.

  440. FLYGT H, Sandin F, Dahlen T, Dremaine A, et al
    Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry.
    Br J Haematol. 2021;193:915-921.
    PubMed     Abstract available

  441. WANG H, Zhou Y, Huang X, Zhang Y, et al
    Minimal residual disease level determined by flow cytometry provides reliable risk stratification in adults with T-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2021;193:1096-1104.
    PubMed     Abstract available

  442. CREUZET E, Nourrisson C, Chaleteix C, Poirier P, et al
    Cerebral aspergillosis in a patient on ibrutinib therapy.
    Br J Haematol. 2021;193:1025.

  443. DANDER E, Fallati A, Gulic T, Pagni F, et al
    Monocyte-macrophage polarization and recruitment pathways in the tumour microenvironment of B-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2021;193:1157-1171.
    PubMed     Abstract available

  444. TSAUR G, Popov A, Riger T, Kustanovich A, et al
    Prognostic value of minimal residual disease measured by fusion-gene transcript in infants with KMT2A-rearranged acute lymphoblastic leukaemia treated according to the MLL-Baby protocol.
    Br J Haematol. 2021;193:1151-1156.
    PubMed     Abstract available

  445. BRIVIO E, Chantrain CF, Gruber TA, Thano A, et al
    Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series.
    Br J Haematol. 2021;193:1172-1177.
    PubMed     Abstract available

  446. BRAS AE, Osmani Z, de Haas V, Jongen-Lavrencic M, et al
    Standardised immunophenotypic analysis of myeloperoxidase in acute leukaemia.
    Br J Haematol. 2021;193:922-927.
    PubMed     Abstract available

    May 2021
  447. CHANDER G, Nikolousis E, Kanellopoulos A
    Human papilloma virus (HPV)-associated lesions in a post-bone marrow transplant patient responding to HPV vaccination.
    Br J Haematol. 2021 May 2. doi: 10.1111/bjh.17514.

  448. ROSS DM
    How much imatinib is enough?
    Br J Haematol. 2021;193:699-700.

  449. KIM DDH, Novitzky-Basso I, Kim TS, Atenafu EG, et al
    Optimal duration of imatinib treatment/deep molecular response for treatment-free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial.
    Br J Haematol. 2021;193:779-791.
    PubMed     Abstract available

  450. KHARFAN-DABAJA MA, Labopin M, Brissot E, Kroger N, et al
    Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia.
    Br J Haematol. 2021;193:592-601.
    PubMed     Abstract available

  451. AOKI K, Kurashige M, Ichii M, Higaki K, et al
    Identification of CXCL12-abundant reticular cells in human adult bone marrow.
    Br J Haematol. 2021;193:659-668.
    PubMed     Abstract available

  452. MIKHAILOVA E, Semchenkova A, Illarionova O, Kashpor S, et al
    Relative expansion of CD19-negative very-early normal B-cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR-T cell therapy: implications for flow cytometric detection of minimal residual disease.
    Br J Haematol. 2021;193:602-612.
    PubMed     Abstract available

  453. SEMBILL S, Gohring G, Schirmer E, Lutterloh F, et al
    Paediatric chronic myeloid leukaemia presenting in de novo or secondary blast phase - a comparison of clinical and genetic characteristics.
    Br J Haematol. 2021;193:613-618.
    PubMed     Abstract available

  454. DE MIGUEL SANCHEZ C, Robles de Castro D, Pison Herrero C, Perez Persona E, et al
    Primary plasma cell leukaemia presenting with flower-shaped nuclei.
    Br J Haematol. 2021;193:689.

  455. CHEN D, Chen W
    Salmon-coloured granules in residual acute myeloid leukaemia with t(8;21)(q22;q22.1); RUNX1-RUNX1T1.
    Br J Haematol. 2021;193:691.

  456. NOY-LOTAN S, Krasnov T, Dgany O, Jeison M, et al
    Incorporation of somatic panels for the detection of haematopoietic transformation in children and young adults with leukaemia predisposition syndromes and with acquired cytopenias.
    Br J Haematol. 2021;193:570-580.
    PubMed     Abstract available

  457. HJORT JAKOBSEN L, Stidsholt Roug A, Kiesbye Ovlisen A, Werenberg Marcher C, et al
    Temporal changes in survival among adult patients with acute myeloid leukaemia in the period 2000-2016: a Danish population-based study.
    Br J Haematol. 2021;193:482-487.
    PubMed     Abstract available

  458. SMOLEJ L
    Skipping a step: what happened to the design of randomized clinical trials in chronic lymphocytic leukaemia?
    Br J Haematol. 2021;193:723-726.
    PubMed     Abstract available

    April 2021
  459. DO C, Best OG, Thurgood L, Hotinski A, et al
    Insight into del17p low-frequency subclones in chronic lymphocytic leukaemia (CLL): data from the Australasian Leukaemia and Lymphoma Group (ALLG)/CLL Australian Research Consortium (CLLARC) CLL5 trial.
    Br J Haematol. 2021 Apr 13. doi: 10.1111/bjh.17394.
    PubMed     Abstract available

  460. ZHENG J, Wu S, Hu Y, Gao L, et al
    Management of ETV6-ABL1-positive childhood acute lymphoblastic leukaemia: report of two cases, a literature review and a call for action.
    Br J Haematol. 2021;193:197-200.

  461. GANESAN P, Jain H, Bagal B, Subramanian PG, et al
    Outcomes in adolescent and young adult acute lymphoblastic leukaemia: a report from the Indian Acute Leukaemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC).
    Br J Haematol. 2021;193:e1-e4.

  462. FITTER S, Bradey AL, Kok CH, Noll JE, et al
    CKLF and IL1B transcript levels at diagnosis are predictive of relapse in children with pre-B-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2021;193:171-175.
    PubMed     Abstract available

  463. TROUSSARD X, Grever MR
    The revised guidelines for the diagnosis and management of hairy cell leukaemia and the hairy cell leukaemia variant.
    Br J Haematol. 2021;193:11-14.

  464. GAILLLARD B, Cornillet-Lefebvre P, Le QH, Maloum K, et al
    Clinical and biological features of B-cell neoplasms with CDK6 translocations: an association with a subgroup of splenic marginal zone lymphomas displaying frequent CD5 expression, prolymphocytic cells, and TP53 abnormalities.
    Br J Haematol. 2021;193:72-82.
    PubMed     Abstract available

  465. SMOLEJ L, Turcsanyi P, Kubova Z, Zuchnicka J, et al
    External validation of International Prognostic Score for asymptomatic early stage chronic lymphocytic leukaemia and proposal of an alternative score.
    Br J Haematol. 2021;193:133-137.
    PubMed     Abstract available

  466. DANILOV AV, Persky DO
    Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.
    Br J Haematol. 2021;193:15-25.
    PubMed     Abstract available

  467. RASTOGI N, Baker S, Man S, Uger RA, et al
    Use of an anti-CD200-blocking antibody improves immune responses to AML in vitro and in vivo.
    Br J Haematol. 2021;193:155-159.
    PubMed     Abstract available

  468. GURNARI C, Breccia M, Di Giuliano F, Scalzulli E, et al
    Early intracranial haemorrhages in acute promyelocytic leukaemia: analysis of neuroradiological and clinico-biological parameters.
    Br J Haematol. 2021;193:129-132.
    PubMed     Abstract available

  469. STILGENBAUER S, Bosch F, Ilhan O, Kisro J, et al
    Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study.
    Br J Haematol. 2021;193:325-338.
    PubMed     Abstract available

  470. DA CUNHA-BANG C, Rostgaard K, Andersen MA, Rotbain EC, et al
    Risk of new malignancies among patients with CLL treated with chemotherapy: results of a Danish population-based study.
    Br J Haematol. 2021;193:339-345.
    PubMed     Abstract available

  471. SOVERINI S, Martelli M, Bavaro L, De Benedittis C, et al
    Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
    Br J Haematol. 2021;193:271-279.
    PubMed     Abstract available

  472. CLAUDIANI S, Apperley JF, Szydlo R, Khan A, et al
    TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia.
    Br J Haematol. 2021;193:346-355.
    PubMed     Abstract available

  473. DILLON R, Potter N, Freeman S, Russell N, et al
    How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML).
    Br J Haematol. 2021;193:231-244.
    PubMed     Abstract available

    March 2021
    Flow cytometry reveals the nuances of clonal haematopoiesis.
    Br J Haematol. 2021;192:949-950.

  475. BECKER MW, Angelucci E
    A large co-operative biological and clinical study to better understand and improve treatment of the rare t(8;16)(p11;p13) acute myeloid leukaemia.
    Br J Haematol. 2021;192:800-802.

  476. LOGHAVI S, DiNardo CD, Furudate K, Takahashi K, et al
    Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia.
    Br J Haematol. 2021;192:1054-1063.
    PubMed     Abstract available

  477. SCHLIEMANN C, Kessler T, Berdel AF, Hemmerle T, et al
    Phase I study of F16IL2 antibody-cytokine fusion with very low-dose araC in acute myeloid leukaemia relapse after allogeneic stem cell transplantation.
    Br J Haematol. 2021;192:e148-e151.

  478. FERRARI A, Ghelli Luserna Di Rora A, Domizio C, Papayannidis C, et al
    Rearrangements of ATP5L-KMT2A in acute lymphoblastic leukaemia.
    Br J Haematol. 2021;192:e139-e144.

  479. RIGOLIN GM, Saccenti E, Melandri A, Cavallari M, et al
    In chronic lymphocytic leukaemia, SLAMF1 deregulation is associated with genomic complexity and independently predicts a worse outcome.
    Br J Haematol. 2021;192:1068-1072.
    PubMed     Abstract available

  480. TIONG IS, Dillon R, Ivey A, Teh TC, et al
    Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia.
    Br J Haematol. 2021;192:1026-1030.
    PubMed     Abstract available

  481. QU S, Li B, Qin T, Xu Z, et al
    Molecular and clinical features of myeloid neoplasms with somatic DDX41 mutations.
    Br J Haematol. 2021;192:1006-1010.
    PubMed     Abstract available

  482. LUNDIN-STROM KB, Biloglav A, Lazarevic V, Behrendtz M, et al
    Parental origin of monosomy 7 in acute leukaemia.
    Br J Haematol. 2021;192:e132-e135.

  483. KAYSER S, Hills RK, Langova R, Kramer M, et al
    Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study.
    Br J Haematol. 2021;192:832-842.
    PubMed     Abstract available

    February 2021
  484. SMOLEJ L, Brychtova Y, Cmunt E, Doubek M, et al
    Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL St
    Br J Haematol. 2021 Feb 22. doi: 10.1111/bjh.17373.
    PubMed     Abstract available

  485. WOUTERS Y, Nevejan L, Louwagie A, Devos H, et al
    Efficacy of ruxolitinib in B-lymphoblastic leukaemia with the PCM1-JAK2 fusion gene.
    Br J Haematol. 2021;192:e112-e115.

  486. WANG J
    Leukaemia blues - an unusual presentation of leukaemia cutis.
    Br J Haematol. 2021;192:676.

  487. GORDON MJ, Huang J, Chan RJ, Bhargava P, et al
    Medical comorbidities in patients with chronic lymphocytic leukaemia treated with idelalisib: analysis of two large randomised clinical trials.
    Br J Haematol. 2021;192:720-728.
    PubMed     Abstract available

  488. EGHOLM GJ, Andersen MA, Andersen CL, Frederiksen H, et al
    Abnormal eosinophil count at CLL diagnosis correlates with shorter treatment free survival.
    Br J Haematol. 2021;192:e81-e84.

  489. HOTINSKI AK, Best OG, Thurgood LA, Lower KM, et al
    A biclonal case of chronic lymphocytic leukaemia with discordant mutational status of the immunoglobulin heavy chain variable region and bimodal CD49d expression.
    Br J Haematol. 2021;192:e77-e81.

  490. ALI AM, Cooper J, Walker A, Jones D, et al
    Adult-onset acute myeloid leukaemia in a patient with germline mutation of CBL.
    Br J Haematol. 2021;192:665-667.

  491. BRAUNSTEIN Z, Mishra A, Staub A, Freud AG, et al
    Clinical outcomes in T-cell large granular lymphocytic leukaemia: prognostic factors and treatment response.
    Br J Haematol. 2021;192:484-493.
    PubMed     Abstract available

  492. FLOETH M, Elges S, Gerss J, Schwoppe C, et al
    Low-density lipoprotein receptor (LDLR) is an independent adverse prognostic factor in acute myeloid leukaemia.
    Br J Haematol. 2021;192:494-503.
    PubMed     Abstract available

  493. MORENO BERGGREN D, Kjellander M, Backlund E, Engvall M, et al
    Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study.
    Br J Haematol. 2021;192:474-483.
    PubMed     Abstract available

  494. DIAMANTI P, Ede BC, Dace PE, Barendt WJ, et al
    Investigating the response of paediatric leukaemia-propagating cells to BCL-2 inhibitors.
    Br J Haematol. 2021;192:577-588.
    PubMed     Abstract available

    January 2021
  495. BRECCIA M
    Autologous stem cell transplantation finds a place in acute promyelocytic leukaemia.
    Br J Haematol. 2021;192:237-238.

  496. ROSS DM, Hughes TP
    Counterpoint: There is a best duration of deep molecular response for treatment-free remission, but it is patient-specific, and that is the challenge.
    Br J Haematol. 2021;192:24-27.
    PubMed     Abstract available

  497. KARAGIANNIS P, Alsdorf W, Tallarek AC, Blohm ME, et al
    Treatment of refractory acute myeloid leukaemia during pregnancy with venetoclax, high-dose cytarabine and mitoxantrone.
    Br J Haematol. 2021;192:e60-e63.

  498. FOUZIA NA, Sharma V, Ganesan S, Palani HK, et al
    Management of relapse in acute promyelocytic leukaemia treated with up-front arsenic trioxide-based regimens.
    Br J Haematol. 2021;192:292-299.
    PubMed     Abstract available

  499. JIN W, Chen L, Liu Y, Chen Q, et al
    A novel KMT2A-USO1 fusion gene-induced de novo secondary acute myeloid leukaemia in a patient initially diagnosed with acute promyelocytic leukaemia.
    Br J Haematol. 2021;192:e32-e36.

  500. OTTAVIANO G, Baird S, Bonney D, Connor P, et al
    The role of immunotherapy in relapse/refractory precursor-B acute lymphoblastic leukaemia: real-life UK/Ireland experience in children and young adults.
    Br J Haematol. 2021;192:e42-e44.

  501. CAVALLINI C, Galasso M, Pozza ED, Chignola R, et al
    Effects of CD20 antibodies and kinase inhibitors on B-cell receptor signalling and survival of chronic lymphocytic leukaemia cells.
    Br J Haematol. 2021;192:333-342.
    PubMed     Abstract available

  502. GALE RP, Saglio G
    Point: Is there a best duration of deep molecular response to achieve therapy-free remission in chronic myeloid leukaemia?
    Br J Haematol. 2021;192:22-23.

  503. MATSUO H, Wakita T, Hiramatsu H, Ohmori K, et al
    Blast cells in acute megakaryoblastic leukaemia with Down syndrome are characterized by low CLEC12A expression.
    Br J Haematol. 2021;192:e7-e11.

  504. MASON CC, Fiol CR, Baker MJ, Nadal-Melsio E, et al
    Identification of genetic targets in acute myeloid leukaemia for designing targeted therapy.
    Br J Haematol. 2021;192:137-145.
    PubMed     Abstract available

  505. FRISANCO OLIVEIRA A, Tansini A, Toledo TR, Balceiro R, et al
    Immunophenotypic characteristics of juvenile myelomonocytic leukaemia and their relation with the molecular subgroups of the disease.
    Br J Haematol. 2021;192:129-136.
    PubMed     Abstract available

  506. RADICH J
    Molecular testing of chronic myeloid leukaemia in low resource areas.
    Br J Haematol. 2021;192:28-32.
    PubMed     Abstract available

  507. DUAN W, Liu X, Jia J, Wang J, et al
    The loss or absence of minimal residual disease of <0.1% at any time after two cycles of consolidation chemotherapy in CBFB-MYH11-positive acute myeloid leukaemia indicates poor prognosis.
    Br J Haematol. 2021;192:265-271.
    PubMed     Abstract available

  508. MILOJKOVIC D, Cross NCP, Ali S, Byrne J, et al
    Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study.
    Br J Haematol. 2021;192:62-74.
    PubMed     Abstract available

    December 2020
  509. NAKAHATA S, Morishita K
    Commentary on: clinical significance of CD28 gene-related activating alterations in adult T-cell leukaemia/lymphoma.
    Br J Haematol. 2020 Dec 14. doi: 10.1111/bjh.17214.

    November 2020
  510. ZHANG X, Suo S, Wang J, Jin J, et al
    IDH1(R132S) -mutated acute lymphoblastic leukaemia resembles Burkitt lymphoma/leukaemia via activating MYC.
    Br J Haematol. 2020 Nov 21. doi: 10.1111/bjh.17199.

  511. SAKAMOTO Y, Ishida T, Masaki A, Takeshita M, et al
    Clinical significance of CD28 gene-related activating alterations in adult T-cell leukaemia/lymphoma.
    Br J Haematol. 2020 Nov 18. doi: 10.1111/bjh.17211.
    PubMed     Abstract available

    October 2020
  512. HERISHANU Y, Levi S, Kamdjou T, Bornstein Y, et al
    Obinutuzumab in the treatment of autoimmune haemolytic anaemia and immune thrombocytopenia in patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma.
    Br J Haematol. 2020 Oct 23. doi: 10.1111/bjh.17105.

    April 2020
  513. AOKI T, Takahashi H, Tanaka S, Shiba N, et al
    Predisposition to prolonged neutropenia after chemotherapy for paediatric acute myeloid leukaemia is associated with better prognosis in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study.
    Br J Haematol. 2020 Apr 26. doi: 10.1111/bjh.16656.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.